Anti-ILT4 compositions and methods
Antibodies targeting ILT4 are developed to block immunosuppression in the tumor microenvironment, enhancing immune cell activation and improving tumor killing activity in cancers with high ILT4 expression.
Patent Information
- Application Number
- CN202380036204.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-09-01
- Filing Date
- 2023-03-23
- Publication Date
- 2024-12-06
AI Technical Summary
There is an unmet need for ILT4 inhibitors that can block HLA-G/ILT4-mediated immunosuppression in the tumor microenvironment, as some tumors become refractory to PD-1/PD-L1 inhibitors and escape T cell-mediated tumor responses.
Development of antibodies or antigen-binding fragments that specifically bind to ILT4, including specific CDR sequences, to block ILT4 activity and reverse immunosuppression, enhancing immune cell activation and antigen presentation.
The antibodies effectively block ILT4 activity, reprogramming myeloid cells, enhancing T cell activation, and improving tumor killing activity, particularly in cancers with high ILT4 expression like NSCLC.
Smart Images

Figure CN119095876A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of priority to U.S. Provisional Application No. 63 / 324,544, filed on March 28, 2022, and U.S. Provisional Application No. 63 / 374,250, filed on September 1, 2022, the disclosures of which are incorporated herein by reference in their entireties.
[0003] Sequence Listing
[0004] The sequence listing submitted with this application via EFS is named "4494-143PCT.xml", created on March 23, 2023, and is 130,000 bytes in size, and is hereby incorporated by reference in its entirety. Technical Field
[0005] The present disclosure relates to the field of biotechnology, and more specifically, to anti-ILT4 antibodies and antigen-binding fragments thereof, and methods and compositions of the anti-ILT4 antibodies and antigen-binding fragments thereof. Background Art
[0006] Immunoglobulin-like transcript 4 (ILT4), also known as leukocyte immunoglobulin-like receptor B2 (LILRB2), is an immunosuppressive molecule that is primarily expressed in myeloid cells, including monocytes, macrophages, dendritic cells and granulocytes, tumor cells, and stromal cells. ILT4 is enriched in tumor cells and stromal cells in the tumor microenvironment of certain malignant diseases. The expression and signaling of ILT4 in myeloid cells create a tumor suppressive microenvironment that favors tumor progression. ILT4 has been shown to bind to a variety of ligands, including human leukocyte antigen G (HLA)-G, major histocompatibility complex class I (MHC-I) proteins (e.g., (HLA-A)), angiopoietin-like proteins (AngptIs), Nogo66, myelin-associated glycoprotein (MAG), oligodendrocyte myelin glycoprotein (OMgp), β-amyloid, semaphorin 4A (Sema4A), CD1c / d, and complement split products (CSP). Among the endogenous ligands of ILT4, human leukocyte antigen G (HLA)-G (which is a non-classical MHC class I molecule) is expressed by a wide range of tumors. HLA-G has been shown to mediate the immune tolerance of cancer by interacting with ILT4. The combination of HLA-G and ILT4 can also directly inhibit the function of monocytes, dendritic cells and neutrophils. Therefore, tumor cells can escape innate and adaptive immune responses by expressing (HLA)-G. The immune tolerance mechanism caused by the interaction of HLA-G / ILT4 includes the impairment of immune cell proliferation, differentiation, cytotoxicity, cytokine secretion and chemotaxis. The interaction between HLA-G and monocytes caused by ILT4 inhibits the maturation of antigen presenting cells (APC) derived from human monocytes, thereby reducing the expression of MHC class II antigens and co-stimulatory molecules through Stat3 activation. Blocking ILT4 can convert suppressed macrophages (M2) into an activated state (M1-like).
[0007] Immune checkpoint inhibitors have become first-line therapies for various malignant diseases. These include programmed cell death protein 1 (PD-1) / programmed cell death ligand 1 (PD-L1) inhibitors used as first-line and second-line therapeutic agents. Programmed cell death 1 protein PD-1 is a member of the CD28 family and is an immunosuppressive receptor expressed on the surface of activated T cells and B cells. The interaction between PD1 and PD-L1 can be blocked to significantly increase the tumor killing activity of CD8+ cytotoxic T cells. Specifically, PD-1 / PD-L1 inhibitors are used to treat patients with non-small cell lung cancer (NSCLC). For example, compared with traditional therapies, PD-1 / PD-L1 inhibitor monotherapy can significantly prolong survival without the side effects observed for therapeutic agents previously used to treat advanced NSCLC. However, some patients carry tumors that are refractory to PD-1 / PD-L1 inhibitors, or become refractory to PD-1 / PD-L1 inhibitors after treatment, and are able to escape T cell-mediated tumor responses.
[0008] Therefore, there is an unmet need for ILT4 inhibitors that can block HLA-G / ILT4-mediated immunosuppression on myeloid cell populations in the tumor microenvironment. Summary of the invention
[0009] The leukocyte immunoglobulin-like receptor (LILR) family contains activating and inhibitory members that can upregulate or downregulate immune cell activity. Inhibitory LILR family members include, but are not limited to, LILRB1 (CD85j / ILT2), LILRB2 (CD85d / ILT4), LILRB3 (CD85a / ILT5), LILRB4 (CD85K, ILT3), and LILRB5 (CD85C); while activating LILR family members include LILRA1 (CD85I), LILRA2 (CD85h / ILT1), LILRA4 (CD85g / ILT7), LILRA5 (CD85f), and LILRA6 (CD85b). LILRA3 (CD85e / ILT6) is expressed only in soluble form.
[0010] The present disclosure relates to antibodies or antigen-binding fragments thereof that bind to ILT4 (ie, LILRB2). In some embodiments, the antibody or antigen-binding fragment thereof that binds to ILT4 comprises a heavy chain variable domain comprising a CDR-H1 comprising an amino acid sequence selected from the group consisting of DYYMN (SEQ ID NO: 1), GYSVN (SEQ ID NO: 9), DSYMN (SEQ ID NO: 23), GYFMN (SEQ ID NO: 30), SYWMN (SEQ ID NO: 38), DYTIH (SEQ ID NO: 46), DNYLQ (SEQ ID NO: 52), DYGMH (SEQ ID NO: 60), and TYGMS (SEQ ID NO: 68); and a CDR-H2 comprising an amino acid sequence selected from the group consisting of DINPNNGGTSYNQKFKG (SEQ ID NO: 2), RINPYNGDIFNNQKFKG (SEQ ID NO: 10), RIYPGVYRTHYNEKFKD (SEQ ID NO: 11). NO:17), YINPDNGVTRYNQKFKG (SEQ ID NO:24), RINPYNGDIFYNQKFKG (SEQ ID NO:31), QIYPGHGDTNYNGKFKG (SEQ ID NO:39), WFYPGTVSIKYNEKFKD (SEQ ID NO:47), PGSGNTYYSDNFTG (SEQ ID NO:53), YISSDSSTIYYADTVKG (SEQ ID NO:61), and WINTYSGEPTYADEFKG (SEQ ID NO:69); and a CDR-H3 comprising an amino acid sequence selected from the group consisting of GGAELTGTYWYFDV (SEQ ID NO:3), GTTVGGAWFAY (SEQ ID NO:11), SGYYGGTYEEDAMDY (SEQ ID NO:18), EGTITTDLSWFAY (SEQ ID NO:19), and EGTITTDLSWFAY (SEQ ID NO:20). NO:25), GITVAAGSFDV (SEQ ID NO:32), EGSELGRLFAY (SEQ ID NO:40), HEHPHYYGDSYDAMGY (SEQ ID NO:48), STVVYFDV (SEQ ID NO:54), RAAQGYVMDY (SEQ ID NO:62) and RGYDGYYYTMDY (SEQ ID NO:70).In some embodiments, the light chain variable domain comprises a CDR-L1 comprising an amino acid sequence selected from the group consisting of RASENIYSNLA (SEQ ID NO:4), RASESVDSYGYSFLH (SEQ ID NO: 12), RASESVDNYGNTFMH (SEQ ID NO:33), SASSVSSFMY (SEQ ID NO:41), SNYAN (SEQ ID NO:55), and KASQSVSDDVA (SEQ ID NO:63); and a CDR-L2 comprising an amino acid sequence selected from the group consisting of GATNLAD (SEQ ID NO:5), LASNLES (SEQ ID NO: 13), AATSLAD (SEQ ID NO: 19), ASTNLAD (SEQ ID NO:26), RASNLES (SEQ ID NO:34), LTSNLAS (SEQ ID NO:42), (SEQ ID NO:53), GTNNRAP (SEQ ID NO:56), ASNRYT (SEQ ID NO:57), NO:64) and AATNLAD (SEQ ID NO:71); and a CDR-L3 comprising an amino acid sequence selected from the group consisting of QHFWDSPFT (SEQ ID NO:6), QQSNEDLMYT (SEQ ID NO: 14), QNFWDTPYT (SEQ ID NO:20), QHFWDTPYT (SEQ ID NO:27), QQSSDHPLT (SEQ ID NO:35), QQWSSNPPT (SEQ ID NO:43), QHFWGTPYT (SEQ ID NO:49), WYSNHWV (SEQ ID NO:57), QQDYGSPT (SEQ ID NO:65) and QHFFGAPWT (SEQ ID NO:72).
[0011] In some aspects, the antibody or antigen-binding fragment thereof that binds to ILT4 comprises the following CDR-H1 sequence: DYYMN (SEQ ID NO: 1), GYSVN (SEQ ID NO: 9), DSYMN (SEQ ID NO: 23), or GYFMN (SEQ ID NO: 30), the following CDR-H2 sequence: DINPNNGGTSYNQKFKG (SEQ ID NO: 2), RINPYNGDIFNNQKFKG (SEQ ID NO: 10), RIYPGVYRTHYNEKFKD (SEQ ID NO: 17), YINPDNGVTRYNQKFKG (SEQ ID NO: 24), or RINPYNGDIFYNQKFKG (SEQ ID NO: 31), or the following CDR-H3 sequence: GGAELTGTYWYFDV (SEQ ID NO: 3), GTTVGGAWFAY (SEQ ID NO: 11), SGYYGGTYEEDAMDY (SEQ ID NO: 12). NO:18), EGTITTDLSWFAY (SEQ ID NO:25) or GITVAAGSFDV (SEQ ID NO:32); and the following CDR-L1 sequences: RASENIYSNLA (SEQ ID NO:4), RASESVDSYGYSFLH (SEQ ID NO:12) or RASESVDNYGNTFMH (SEQ ID NO:33), the following CDR-L2 sequences: GATNLAD (SEQ ID NO:5), LASNLES (SEQ ID NO:13), AATSLAD (SEQ ID NO:19), ASTNLAD (SEQ ID NO:26) or RASNLES (SEQ ID NO:34), and the following CDR-L3 sequences: QHFWDSPFT (SEQ ID NO:6), QQSNEDLMYT (SEQ ID NO:14), QNFWDTPYT (SEQ ID NO:20), QHFWDTPYT (SEQ ID NO:27) or QQSSDHPLT (SEQ ID NO:35).
[0012] In certain aspects, the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable domain CDR comprising an amino acid sequence of DYYMN (SEQ ID NO: 1), DINPNNGGTSYNQKFKG (SEQ ID NO: 2), and GGAELTGTYWYFDV (SEQ ID NO: 3), and a light chain variable domain CDR comprising an amino acid sequence of RASENIYSNLA (SEQ ID NO: 4), GATNLAD (SEQ ID NO: 5), and QHFWDSPFT (SEQ ID NO: 6); (b) a heavy chain variable domain CDR comprising an amino acid sequence of GYSVN (SEQ ID NO: 9), RINPYNGDIFNNQKFKG (SEQ ID NO: 10), and GTTVGGAWFAY (SEQ ID NO: 11), and a light chain variable domain CDR comprising an amino acid sequence of RASESVDSYGYSFLH (SEQ ID NO: 12), LASNLES (SEQ ID NO: 13), and QQSNEDLMYT (SEQ ID NO: 14). NO: 14); (c) a heavy chain variable domain CDR comprising an amino acid sequence of DYYMN (SEQ ID NO: 1), RIYPGVYRTHYNEKFKD (SEQ ID NO: 17) and SGYYGGTYEEDAMDY (SEQ ID NO: 18), and a light chain variable domain CDR comprising an amino acid sequence of RASENIYSNLA (SEQ ID NO: 4), AATSLAD (SEQ ID NO: 19) and QNFWDTPYT (SEQ ID NO: 20); (d) a heavy chain variable domain CDR comprising an amino acid sequence of DYYMN (SEQ ID NO: 1), RIYPGVYRTHYNEKFKD (SEQ ID NO: 17) and SGYYGGTYEEDAMDY (SEQ ID NO: 18), and a light chain variable domain CDR comprising an amino acid sequence of RASENIYSNLA (SEQ ID NO: 4), AATSLAD (SEQ ID NO: 19) and QNFWDTPYT (SEQ ID NO: 20). NO:20); or (e) a heavy chain variable domain CDR comprising the amino acid sequence of DSYMN (SEQ ID NO:23), YINPDNGVTRYNQKFKG (SEQ ID NO:24) and EGTITTDLSWFAY (SEQ ID NO:25), and a light chain variable domain CDR comprising the amino acid sequence of RASENIYSNLA (SEQ ID NO:4), ASTNLAD (SEQ ID NO:26) and QHFWDTPYT (SEQ ID NO:27).
[0013] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable domain comprising an amino acid sequence that is at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following amino acid sequence:
[0014] DIQMTQSPASLSISVGETVTITCRASENIYSNLAWYQQKQGKSPQVLVYGATNLADGVPSRFSGSGSGTQYSLKIKSLQSEDFGSYYCQHFWDSPFTFGSGTKLEIK(SEQ ID NO:8),
[0015] VIVLTQSPASLAVSLGQRAAISCRASESVDSYGYSFLHWYQQKPGQPPKLLIYLASNLESGIPARFSGSGSGTDFTLTINPVEADDVATYYCQQSNEDLMYTFGGGTKLEIK(SEQ ID NO:16),
[0016] DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYAATSLADGVPSRFRGSGSGTQYSLKISSLQSEDFGNYYCQNFWDTPYTFGGGTKLEIK(SEQ ID NO:22),
[0017] DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYASTNLADGAPATFSGSGSGTQYSLKINSLQSVDFGSYYCQHFWDTPYTFGGGTKLEIK(SEQ ID NO:29),
[0018] DIVLTQSPASLAVSLGQRATISCRASESVDNYGNTFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSKTDFTLTINPVEADDVATYYCQQSSDHPLTFGAGTKLELS(SEQ ID NO:37),
[0019] QIVLTQSPALMSASPGEKVTMTCSASSSVSFMYWYQQKPRSSPKPWIYLTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPPTFGGGTKLEIK(SEQ ID NO:45),
[0020] DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYGATNLADGVPSRFGGSGSGTQYSLKINSLQPEDFGSYYCQHFWGTPYTFGGGTKLEIT(SEQ ID NO:51),
[0021] QAVVTQESALTTSPGETVTLTCRSSTGTVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDQAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTVL(SEQ ID NO:59),
[0022] SIVMTQTPKFLLVSAGDRVTITCKASQSVSDDVAWYQQKPGQSPKLLIYYASNRYTGVPDRFTGSGYGTDFTFTISTVQAEDLAVYFCQQDYGSPTFGGGTKLEIK(SEQ ID NO:67), or
[0023] DIQMTQSPASLSASVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVSAATNLADGVPSRFSGSGSGTQFSLKINSLQPEDFGSYYCQHFFGAPWTFGGGTKLEIK (SEQ ID NO:74); and a heavy chain variable domain comprising an amino acid sequence that is at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the following amino acid sequence:
[0024] EVQLQQSGPELVKPGASVKISCKASGYTFTDYYMNWVKQSHGKSLEWIGDINPNNGGTSYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCARGGAELTGTYWYFDVWGTGTTVTVSS(SEQ ID NO:7),
[0025] DVQLQQSGPELVKPGNSVKISCKAAGYSFTGYSVNWVKERHGKSLEWIGRINPYNGDIFNNQKFKGKATLTVDKSSSTAHMELRSLTSEDSAVYYCARGTTVGGAWFAYWGQGTLVTVSA(SEQ ID NO:15)、
[0026] QVQLKQSGAELVRPGASVKLSCRASGYTFTDYYMNWVKQRPGQGLEWIARIYPGVYRTHYNEKFKDKATLTAEKSSSTAYMELSSLTSEDSAVYFCARSGYYGGTYEEDAMDYWGQGTSVTVSS(SEQ ID NO:21)、
[0027] EVQLQQSGPELVIPGASVKISCKASGYTFTDSYMNWVKQSHGKSLEWIAYINPDNGVTRYNQKFKGKATLTVHKSSSTAYMELRSLTSEDSAVYYCAREGTITTDLSWFAYWGQGTLVTVSA(SEQ ID NO:28)、
[0028] EVHLQQSGPELVKPGASVKISCKASGYSFIGYFMNWMKQSHGKSLEWIGRINPYNGDIFYNQKFKGKATLTVDKSSTTAHMDLLSLTSEDFAVYYCARGITVAAGSFDVWGTGTTVTVSS(SEQ ID NO:36)、
[0029] QVQLQQSGAELVKPGASVKISCKASGYAFSSYWMNWVKQRPGKGLEWIGQIYPGHGDTNYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCAKEGSELGRLFAYWGQGTLVTVSA(SEQ ID NO:44)、
[0030] QVQLQQSGTELVKPGASVKLSCKASGYIFTDYTIHWVKQRSGQGLEWIGWFYPGTVSIKYNEKFKDKATLTADRSSSIVYMELSRLTSEDSGVYFCARHEHPHYYGDSYDAMGYWGQGTSVTVSS(SEQ ID NO:50)、
[0031] QVQLQQSGPELVKPGASVKISCKASGYIFTDNYLQWVKQRPGQGLEWIGWIFPGSGNTYYSDNFTGKATLTVDKSSITAYMLLSSLTSEDSAVYFCSRSTVVYFDVWGTGTTVTVSS(SEQ ID NO:58),
[0032] EVQLVESGGGLVKPGGSLKLSCAASGFTFSDYGMHWVRQAPEKRLEWVAYISSDSSTIYYADTVKGRFTISRDNAKNTLFLEMTSLRSEDTAMYYCARRAAQGYVMDYWGQGTSVTVSS(SEQ ID NO:66), or
[0033] QIQLVQSGPELKKPGETVKISCKASGYTFTTYGMSWVKQAPGKGLKWMAWINTYSGEPTYADEFKGRFAFSLETSVSTAYLQINNLKNEDTATYFCARRGYDGYYYTMDYWGQGTSVTVSS (SEQ ID NO: 73).
[0034] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable domain comprising an amino acid sequence that is at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:8, 16, 22, 29 or 37; and a heavy chain variable domain comprising an amino acid sequence that is at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:7, 15, 21, 28 or 36.
[0035] In some aspects, the antibody or antigen-binding fragment thereof comprises a light chain variable domain comprising the amino acid sequence shown in SEQ ID NO:8, 16, 22, 29 or 37; and a heavy chain variable domain comprising the amino acid sequence shown in SEQ ID NO:7, 15, 21, 28 or 36.
[0036] In certain embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain variable domain comprising the amino acid sequence of EVQLQQSGPELVKPGASVKISCKASGYTFTDYYMNWVKQSHGKSLEWIGDINPNNGGTSYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCARGGAELTGTYWYFDVWGTGTTVTVSS (SEQ ID NO: 7), and (b) a heavy chain variable domain comprising the amino acid sequence of DIQMTQSPASLSISVGETVTITCRASENIYSNLAWYQQKQGKSPQVLVYGATNLADGVPSRFSGSGSGTQYSLKIKSLQSEDFGSYYCQHFWDSPFTFGSGTKLEIK (SEQ ID NO: 8). (a) a light chain variable domain comprising the amino acid sequence of DVQLQQSGPELVKPGNSVKISCKAAGYSFTGYSVNWVKERHGKSLEWIGRINPYNGDIFNNQKFKGKATLTVDKSSSTAHMELRSLTSEDSAVYYCARGTTVGGAWFAYWGQGTLVTVSA (SEQ ID NO: 15), and a heavy chain variable domain comprising the amino acid sequence of VIVLTQSPASLAVSLGQRAAISCRASESVDSYGYSFLHWYQQKPGQPPKLLIYLASNLESGIPARFSGSGSGTDFTLTINPVEADDVATYYCQQSNEDLMYTFGGGTKLEIK (SEQ ID NO: 16). (c) a heavy chain variable domain comprising the amino acid sequence of QVQLKQSGAELVRPGASVKLSCRASGYTFTDYYMNWVKQRPGQGLEWIARIYPGVYRTHYNEKFKDKATLTAEKSSSTAYMELSSLTSEDSAVYFCARSGYYGGTYEEDAMDYWGQGTSVTVSS (SEQ ID NO:21), and a light chain variable domain comprising the amino acid sequence of DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYAATSLADGVPSRFRGSGSGTQYSLKISSLQSEDFGNYYCQNFWDTPYTFGGGTKLEIK (SEQ ID NO:22);(d) a heavy chain variable domain comprising the amino acid sequence of EVQLQQSGPELVIPGASVKISCKASGYTFTDSYMNWVKQSHGKSLEWIAYINPDNGVTRYNQKFKGKATLTVHKSSSTAYMELRSLTSEDSAVYYCAREGTITTDLSWFAYWGQGTLVTVSA (SEQ ID NO: 28), and a heavy chain variable domain comprising the amino acid sequence of DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYASTNLADGAPATFSGSGSGTQYSLKINSLQSVDFGSYYCQHFWDTPYTFGGGTKLEIK (SEQ ID NO: 29). or (e) a heavy chain variable domain comprising the amino acid sequence of EVHLQQSGPELVKPGASVKISCKASGYSFIGYFMNWMKQSHGKSLEWIGRINPYNGDIFYNQKFKGKATLTVDKSSTTAHMDLLSLTSEDFAVYYCARGITVAAGSFDVWGTGTTVTVSS (SEQ ID NO:36), and a light chain variable domain comprising the amino acid sequence of DIVLTQSPASLAVSLGQRATISCRASESVDNYGNTFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSKTDFTLTINPVEADDVATYYCQQSSDHPLTFGAGTKLELS (SEQ ID NO:37). ;
[0037] In one embodiment, the antibody or antigen-binding fragment thereof comprises: 1 X 2 X 3 X 4 The amino acid sequence of CDR-H1 of N, wherein X 1 D or G, X 2 Y or S, X 3 is Y, S or F, and X 4 M or V; contains X 1 IX 2 PX 3 X 4 X 5 X 6 X 7 X 8 X 9 NX 10 KFK 11 (SEQ ID No: 76), wherein X1 R, D or Y, X 2 N or Y, X 3 is G, N, D or Y, X 4 V or N, X 5 G or Y, X 6 R, G, V or D; X 7 I or T, X 8 H, S, R or F; X 9 is Y or N, X 10 is E or Q, X 11 is D or G; and contains X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 The amino acid sequence of CDR-H3, wherein X 1 G, S or E, X 2 G, T or I, X 3 A, T or Y, X 4 E, V, Y, or I; X 5 L, G, T or A; X 6 T, G or A, X 7 is G, A, T or D, X 8 T, W, Y, L or S, X 9 is Y, F, E or S, X 10 W, A, E or D, X 11 is Y, D, F or V, X 12 F, A or not present, X 13 D, M, Y or not present, X 14 is V, D or does not exist, and X 15 Is Y or does not exist.
[0038] In one embodiment, the antibody or antigen-binding fragment thereof comprises: a light chain variable domain comprising: a RASEX 1 X 2 X 3 X4X 5 X 6 X7X 8 X 9 X 10(SEQ ID NO: 78), wherein X 1 N or S, X 2 I or V, X 3 is Y or D, X 4 S or N, X 5 N or Y, X 6 L or G, X 7 or A 、 Y or N, X 8 is S, T or does not exist, X 9 F or not present, X 10 L, M or not present; contains X 1 X 2 X 3 X 4 LX 5 X 6 The amino acid sequence of CDR-L2, wherein X 1 L, R, G or A, X 2 A or S, X 3 For S or T, X 4 N or S, X 5 is E or A, and X 6 is S or D; and contains X 1 QX 2 X 3 X 4 DX 5 X 6 X 7 The amino acid sequence of CDR-L3 of T, wherein X 1 Does not exist or is Q, X 2 is S, H, N or Q, X 3 N, F or S, X 4 E, W or S, X 5 L, S, T or H, X 6 is M or P, and X 7 It is Y, F or L.
[0039] In some embodiments, an antibody or antigen-binding fragment thereof that binds to ILT4 comprises a heavy chain variable domain CDR comprising DYYMN (SEQ ID NO: 1), IYPGVYRT (SEQ ID NO: 113) and SGYYGGTYEEDAMDY (SEQ ID NO: 18); and a light chain variable domain CDR comprising ENIYSN (SEQ ID NO: 114), AAT and QNFWDTPYT (SEQ ID NO: 20). In some embodiments, an antibody or antigen-binding fragment thereof that binds to ILT4 comprises a heavy chain variable domain CDR comprising DYYMN (SEQ ID NO: 1), INPNNGGT (SEQ ID NO: 116) and GGAELTGTYWYFDV (SEQ ID NO: 3); and a light chain variable domain CDR comprising ENIYS (SEQ ID NO: 117), GAT and QHFWDSPFT (SEQ ID NO: 6). In some embodiments, an antibody or antigen-binding fragment thereof that binds to ILT4 comprises a heavy chain variable domain CDR comprising GYSVN (SEQ ID NO: 9), INPYNGDI (SEQ ID NO: 119), and GTTVGGAWFAY (SEQ ID NO: 11); and a light chain variable domain CDR comprising ESVDSYGYSF (SEQ ID NO: 120), LAS, and QQSNEDLMYT (SEQ ID NO: 14). In some embodiments, an antibody or antigen-binding fragment thereof that binds to ILT4 comprises a heavy chain variable domain CDR comprising GYFMN (SEQ ID NO: 30), INPYNGDI (SEQ ID NO: 119), and GITVAAGSFDV (SEQ ID NO: 32); and a light chain variable domain CDR comprising ESVDNYGNTF (SEQ ID NO: 122), RAS, and QQSSDHPLT (SEQ ID NO: 35).
[0040] The present disclosure also relates to a method for treating a subject with an autoimmune, neoplastic or inflammatory condition, comprising administering an antibody or antigen binding fragment that binds to ILT4. In some aspects, the present disclosure relates to a method for treating a subject with cancer. In some embodiments, the cancer is a solid cancer or a liquid cancer. In one aspect, the cancer is a carcinoma or a sarcoma. Specifically, the median ILT4 expression in non-small cell lung cancer (NSCLC) is particularly high compared to other cancers, and the prognosis of NSCLC patients with high ILT4 expression is poor compared to NSCLC patients with low ILT4 expression.
[0041] In some embodiments, the method includes a) blocking the interaction between ILT4 and HLA-G; b) downregulating ILT4 activity or HLA-G levels; c) removing immunosuppression of ILT4 or HLA-G; d) enhancing monocyte activation; or e) any combination of a) to d). In some embodiments, the method includes treating cancer or reducing the severity of cancer by reversing or reducing immunosuppression, which is performed by administering an antibody or antigen-binding fragment thereof that binds to ILT4. In some embodiments, the reversal or reduction of immunosuppression includes reprogramming myeloid cells by administering an antibody or antigen-binding fragment thereof that binds to ILT4. In some aspects, the present disclosure includes improving T cell activation in a subject by administering an antibody or antigen-binding fragment of the present disclosure. In some aspects, the present disclosure includes improving antigen presentation for T cell priming in a subject by administering an antibody or antigen-binding fragment of the present disclosure. In some aspects, the present disclosure includes promoting macrophage reprogramming in a subject by administering an antibody or antigen-binding fragment of the present disclosure. In some aspects, the present disclosure includes activating dendritic cells in a subject by administering an antibody or antigen-binding fragment of the present disclosure. In some aspects, the present disclosure includes increasing T cell co-stimulation in a subject by administering an antibody or antigen-binding fragment of the present disclosure.
[0042] The present disclosure also relates to a method of inducing apoptosis in cancer cells or cancer stem cells, comprising contacting the cancer cells or cancer stem cells with an antibody or an antigen-binding fragment thereof that binds to ILT4.
[0043] Other features and characteristics of the subject matter of the present disclosure, as well as the methods of operation, the functions of the related elements of structure and the combination of parts, and the economy of manufacture will become more apparent after consideration of the following description and the accompanying drawings, sequence listing and claims, all of which constitute a part of this specification. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1A and 1BShown are TNF-α levels in supernatants from monocyte-derived macrophages of (A) Donor A and (B) Donor B, respectively. Cells were treated with the indicated antibodies at the indicated concentrations (μg / ml).
[0046] Figure 2A and 2B Shown are IL-6 levels in supernatants of monocyte-derived macrophages from (A) Donor A and (B) Donor B, respectively. Cells were treated with the indicated antibodies at the indicated concentrations (μg / ml).
[0047] Figure 3A and 3B Shown are CD206 mean fluorescence intensities of monocyte-derived macrophages from (A) Donor A and (B) Donor B, respectively. Cells were treated with the indicated antibodies at the indicated concentrations (μg / ml).
[0048] Figure 4A and 4B Shown are CD209 mean fluorescence intensities of monocyte-derived macrophages from (A) donor A and (B) donor B, respectively. Cells were treated with the indicated antibodies at the indicated concentrations (μg / ml).
[0049] Figure 5 Shown are the cell-associated fluorescence of CHO-S parental and CHO-S / ILT4 cell lines after incubation with PE-conjugated HLA-G.
[0050] Figure 6 Shown are cell-associated fluorescence after pre-incubation with the indicated mouse anti-human ILT4 antibodies prior to PE-HLA-G incubation.The results measure the blocking effect of the candidate mouse anti-human ILT4 antibodies on HLA-G.
[0051] Figure 7 Shown are the IC values from an exemplary ILT4 antibody blocking assay using flow cytometry. 50 curve.
[0052] Figure 8 Shown is the blocking activity of humanized anti-ILT4 antibodies on HLA-G binding to ILT4-expressing CHO cells. The graph is representative of n = 3. Each data point is the mean plus SD of three replicates.
[0053] Fig. 9 Shown is the blocking activity of humanized anti-ILT4 antibodies on HLA-A binding to ILT4-expressing CHO cells. The graph is representative of n = 3. Each data point is the mean plus SD of three replicates.
[0054] Fig.10Shown is the effect of anti-ILT4 mAb on TNFa production from macrophages. TNF-a levels in the supernatant of monocyte-derived macrophages from donors 4 and 5, respectively. Cells were treated with 4ug / ml of the indicated antibodies and titrated 1:4 at 8 concentration points. Anti-ILT4 antibodies and LPS were added 24 hours before evaluation.
[0055] Fig.11 The effect of anti-ILT4 mAb on IL-6 production from macrophages is shown. TNF-a levels in the supernatant of monocyte-derived macrophages from (A) donor 4 and (B) donor 5, respectively. Cells were treated with 4ug / ml of the indicated antibodies and titrated 1:4 at 8 concentration points. Anti-ILT4 antibodies and LPS were added 24 hours before evaluation.
[0056] Fig.12 The effect of anti-ILT4 mAb on the expression of cell surface markers on macrophages before and after treatment is shown. Flow cytometry data show that the mean fluorescence intensity (MFI) of monocyte-derived macrophages has doubled compared to control staining. This data compares the expression levels of CD206, ILT4 and CD163 before (culture medium) and after treatment with 4ug / ml anti-ILT4 antibody.
[0057] Fig.13 MLR assays for assessing T cell activation are shown. M2 macrophages and CD4 T cells were plated at a 1:5 ratio in the presence of anti-ILT4 antibody or anti-ILT4 antibody + anti-PD-1 antibody (Tori). (A) Donor 1 and (B) Donor 2. IgG1 (hIgG1 LALA isotype control).
[0058] Fig.14 Anti-ILT4 mAbs are shown competing with AF647-Hz45.01-LALA for binding to ILT4-CHO cells.
[0059] Fig.15 Will come from Fig.14 The data of Hz45.01-LALA versus 1E1 and HuIgG1-LALA (as controls) are plotted on the same graph (left), and the data of Hz45.01-LALA versus J19h1 and HuIgG1-LALA (as controls) are plotted on the same graph (right).
[0060] Fig.16 Anti-ILT4 mAbs are shown competing with AF647-Hz156.03-LALA for binding to ILT4-CHO cells.
[0061] Fig.17 Will come from Fig.16 The data of Hz45.01-LALA versus 1E1 and HuIgG1-LALA (as controls) are plotted on the same graph (left), and the data of Hz45.01-LALA versus J19h1 and HuIgG1-LALA (as controls) are plotted on the same graph (right).
[0062] Fig.18 Shown is the binding of AF647-Hz45.01-LALA and AF647-Hz156.03-LALA to ILT4-CHO cells incubated with ILT4-CHO cells at various concentrations (0-10 μg / ml) and analyzed by flow cytometry. DETAILED DESCRIPTION
[0063] Although aspects of the subject matter of the present disclosure may be embodied in various forms, the following description is intended to disclose only some of these forms as specific examples of the subject matter encompassed by the present disclosure. Therefore, the subject matter of the present disclosure is not intended to be limited to the described forms or embodiments.
[0064] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those of ordinary skill in the art to which the invention belongs. Methods and materials for use in the present invention are described herein; other suitable methods and materials known in the art may also be used. The materials, methods, and examples are illustrative only and are not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated herein by reference in their entirety. In the event of a conflict, the present specification (including definitions) shall prevail.
[0065] Other features and advantages of the invention will be apparent from the following detailed description and drawings, and from the claims.
[0066] The present disclosure also relates to a humanized immunoglobulin with binding specificity to ILT4, which comprises an antigen binding region of non-human origin and an immunoglobulin of at least a portion of human origin. In one aspect, the humanized immunoglobulin comprises an antigen binding region of non-human origin that binds to ILT4 and a constant region derived from a human constant region. In another embodiment, the humanized immunoglobulin that binds to ILT4 comprises a complementary determining region of non-human origin and a variable framework region of human origin, and an optional constant region of human origin. For example, the humanized immunoglobulin may comprise a heavy chain and a light chain, wherein the light chain comprises a complementary determining region derived from an antibody of non-human origin that binds to ILT4 and a framework region from a light chain of human origin, and the heavy chain comprises a complementary determining region derived from an antibody of non-human origin that binds to ILT4 and a framework region from a heavy chain of human origin.
[0067] The present disclosure also relates to a humanized immunoglobulin light chain or a humanized immunoglobulin heavy chain. In one aspect, the present disclosure relates to a humanized light chain comprising one or more non-human origin light chain CDRs and a human light chain framework region. On the other hand, the present disclosure relates to a humanized immunoglobulin heavy chain comprising one or more non-human origin heavy chain CDRs and a human heavy chain framework region. The CDRs may be derived from a non-human immunoglobulin.
[0068] Naturally occurring immunoglobulins have a common core structure in which two identical light chains (about 24 kDa) and two identical heavy chains (about 55 or 70 kDa) form a tetramer. The amino terminal portion of each chain is called the variable (V) region and can be distinguished from the more conserved constant (C) region of the remainder of each chain.
[0069] Human immunoglobulins can be divided into classes and subclasses based on the isotype of the heavy chain. The classes include IgG, IgM, IgA, IgD, and IgE, wherein the heavy chains are of the gamma (γ), mu (μ), alpha (α), delta (δ), or epsilon (ε) type, respectively. The subclasses include IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2, wherein the heavy chains are of the gamma 1, gamma 2, gamma 3, gamma 4, alpha 1, and alpha 2 types, respectively. Human immunoglobulin molecules of the selected class or subclass may contain either kappa (κ) or lambda (λ) light chains.
[0070] Antibodies to appropriate immunogens can be produced in suitable mammals (e.g., mice, rats, rabbits or sheep). Cells (e.g., lymphocytes) producing antibodies can be isolated from, for example, lymph nodes or spleens of immunized animals. The cells are then fused with suitable immortalized cells (e.g., myeloma cell lines) to form hybridomas. Selective culture techniques using conventional methods known to those of ordinary skill in the art can be used to separate fused cells. Cells producing antibodies with desired specificity can be selected by suitable assays (e.g., ELISA). Immunoglobulins of non-human origin with binding specificity to ILT4 can also be obtained from antibody libraries (e.g., phage libraries comprising non-human Fab molecules).
[0071] In one embodiment, the antigen binding region of the humanized immunoglobulin comprises a CDR of non-human origin. In this embodiment, the humanized immunoglobulin with binding specificity to ILT4 comprises at least one CDR of non-human origin. For example, CDR can be derived from the light chain and heavy chain variable region of the immunoglobulin of non-human origin, so that the humanized immunoglobulin basically comprises the heavy chain CDR1, CDR2 and / or CDR3 of the immunoglobulin from one or more non-human origins, and / or light chain CDR1, CDR2 and / or CDR3, and the resulting humanized immunoglobulin has binding specificity to ILT4. In some aspects, all three CDRs of the selected chain are substantially the same as the CDRs of the corresponding chains of the donor, and in some aspects, all three CDRs of the light chain and the heavy chain are substantially the same as the CDRs of the corresponding donor chains.
[0072] The part (people's part) of the people's origin of humanized immunoglobulin or immunoglobulin chain can be derived from any suitable human immunoglobulin or immunoglobulin chain. For example, a human constant region or a portion thereof (if present) can be derived from a kappa or lambda light chain of a human antibody (including allele variants), and / or a g (e.g., γ1, γ2, γ3, γ4), μ, α (e.g., α1, α2), δ or ε heavy chain. A specific constant region (e.g., IgG1), a variant or a portion thereof can be selected to customize effector functions. For example, a mutated constant region (variant) can be used to minimize the ability to bind to Fc receptors and / or fix complement.
[0073] The terms "a" and "an" refer to one or more than one (ie, at least one) of the grammatical object of the article. For example, "a cell" encompasses one or more cells.
[0074] As used herein, the terms "about" and "approximately" when used to modify a value or an amount specified in a range, refer to that value and reasonable deviations from that value known to those skilled in the art. For example, ±20%, ±10%, or ±5% may be within the intended meaning of the recited values, where appropriate. The values given are approximate, meaning that if the term "about," "approximately," or "approximately" is not explicitly stated, the term can be inferred.
[0075] Concentration, amount and other numerical data can be represented or presented in the format of range in this article.It should be understood that such range format is only used for convenience and simplicity, and therefore should be flexibly interpreted as not only including the numerical value clearly listed as range limit, but also including all individual numerical values or sub-ranges covered within the range, as if each numerical value and sub-range are clearly stated.As an illustration, the numerical range "about 0.01 to 2.0" should be interpreted as not only including the value of about 0.01 to about 2.0 clearly listed, but also including individual values and sub-ranges within the indicated range.Therefore, included in the numerical range are individual values such as 0.5, 0.7 and 1.5, and sub-ranges such as 0.5 to 1.7, 0.7 to 1.5 and 1.0 to 1.5, etc. In addition, such an explanation should be applicable to the breadth of the range or the described features.In addition, it should be noted that, unless otherwise stated, all percentages are by weight.
[0076] In understanding the scope of the present disclosure, the terms "include" or "comprising" and their derivatives as used herein are intended to be open terms, which specify the existence of stated features, elements, components, groups, wholes and / or steps, but do not exclude the existence of other unstated features, elements, components, groups, wholes and / or steps. The foregoing also applies to words with similar meanings, such as the terms "include", "have" and their derivatives. The terms "consisting of ... " and their derivatives as used herein are intended to be closed terms, which specify the existence of stated features, elements, components, groups, wholes and / or steps, but exclude the existence of other unstated features, elements, components, groups, wholes and / or steps. The term "consisting of ... " as used herein is intended to specify the existence of stated features, elements, components, groups, wholes and / or steps and those that do not substantially affect one or more basic and novel characteristics of features, elements, components, groups, wholes and / or steps. It should be understood that the reference to any of these transitional terms (i.e., "comprising", "consisting of ... " or "consisting of ... ") provides direct support for replacement with any other transitional terms that are not specifically used. For example, modifying the term from "comprising" to "consisting essentially of" or "consisting of" would gain immediate support due to such definition of any element disclosed throughout this disclosure. Based on such definition, any element disclosed herein or incorporated by reference may be included in or excluded from the claimed invention.
[0077] As used herein, for convenience, multiple compounds, elements or steps may be presented in a common list. However, these lists should be interpreted as if each member of the list were individually identified as a separate and unique member. Therefore, in the absence of contrary indications, any individual member of such a list should not be interpreted as a de facto equivalent of any other member of the same list based solely on their presentation in a common group.
[0078] In addition, certain molecules, constructs, compositions, elements, parts, excipients, diseases, disorders, characteristics, steps, etc. may be discussed in the context of a specific embodiment or aspect or in a separate paragraph or section of the disclosure. It should be understood that this is merely for convenience and brevity, and that any such disclosure is equally applicable and intended to be combined with any other embodiment or aspect appearing anywhere in the disclosure, drawings, and claims, all of which constitute the present application and the claimed invention as of the filing date. For example, a list of constructs, molecules, method steps, kits, or compositions described with respect to a construct, composition, or method is intended to and does find direct support for embodiments involving constructs, compositions, formulations, and methods described in any other part of the disclosure, even if those method steps, active agents, kits, or compositions are not listed again in the context or section of that embodiment or aspect.
[0079] Unless otherwise indicated, a "nucleic acid sequence" encoding a "protein" or "polypeptide" includes all nucleotide sequences that are degenerate versions of each other and therefore encode the same amino acid sequence.
[0080] The term "exogenous" refers to any substance introduced into or derived from outside a cell, tissue or organism that is not produced by or derived from the same cell, tissue or organism into which it was introduced.
[0081] The terms "transduction," "transfection," or "transformation" refer to the process of introducing or transferring exogenous nucleic acid into a cell. A "transduced," "transfected," or "transformed" cell (e.g., a mammalian cell) is a cell that has been transduced, transfected, or transformed with an exogenous nucleic acid (e.g., a vector), including an exogenous nucleic acid encoding any of the molecules described herein.
[0082] The term "nucleic acid" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) or a combination thereof in single-stranded or double-stranded form. Unless otherwise specified, the term encompasses nucleic acids containing known natural nucleotide analogs that have binding properties similar to reference nucleotides. Unless otherwise specified, a specific nucleic acid sequence also implicitly encompasses complementary sequences as well as sequences explicitly specified. In some embodiments of any nucleic acid described herein, the nucleic acid is DNA. In some embodiments of any nucleic acid described herein, the nucleic acid is RNA.
[0083] Modifications can be introduced into the nucleotide sequence by standard techniques known in the art (such as site-directed mutagenesis and polymerase chain reaction (PCR)-mediated mutagenesis). Conservative amino acid substitutions are amino acid substitutions in which the amino acid residue is replaced by an amino acid residue with a similar side chain. Families of amino acid residues with similar side chains have been defined in the art. These families include: amino acids with acidic side chains (e.g., aspartic acid and glutamic acid), amino acids with basic side chains (e.g., lysine, arginine, and histidine), nonpolar amino acids (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, and tryptophan), uncharged polar amino acids (e.g., glycine, asparagine, glutamine, cysteine, serine, threonine, and tyrosine), hydrophilic amino acids (e.g., arginine, asparagine, aspartic acid, glutamine, glutamic acid, histidine, lysine, serine, and threonine), hydrophobic amino acids (e.g., alanine, cysteine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, tyrosine, and valine). Other amino acid families include: aliphatic hydroxy amino acids (e.g., serine and threonine), amide family (e.g., asparagine and glutamine), aliphatic family (e.g., alanine, valine, leucine, and isoleucine), and aromatic family (e.g., phenylalanine, tryptophan, and tyrosine).
[0084] "Affinity" refers to the strength of the sum of all non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen or Fc receptor). Unless otherwise indicated, as used herein, "binding affinity" refers to the intrinsic binding affinity (microscopic equilibrium dissociation constant) that reflects a 1:1 interaction between members of a binding pair (e.g., antibody / Fc receptor or antibody and antigen). The affinity of a molecule X for its partner Y can generally be expressed in terms of the dissociation constant (K D ). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described in this disclosure and are known to those skilled in the art.
[0085] The term "antibody fragment" or "antibody binding fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab') 2 ; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.
[0086] As used herein, the terms "cytotoxin" and "cytotoxic agent" refer to substances that inhibit or prevent cellular function and / or cause cell death or destruction. Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At 211 ,I 131 ,I 125 , Y 90 、Re 186 、Re 188 、Sm 153 ,、Bi 212 , P 32 , Pb 212 and radioactive isotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate, doxorubicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth inhibitors; enzymes and fragments thereof such as nucleolytic enzymes; antibiotics; toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and / or variants thereof; and various anti-tumor or anti-cancer agents disclosed below.
[0087] A "chemotherapeutic agent" is a compound useful in the treatment of cancer. Non-limiting examples of chemotherapeutic agents include alkalyzing or alkylating agents such as thiotepa and cyclosphamide (CYTOXAN TM); alkyl sulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethyleneimines and methylamelamines, including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylolomelamine; nitrogen mustards mustards such as chlorambucil, naphthyl mustard, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide; melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine;Antibiotics such as aclacinomycin, actinomycin, authramycin, azaserine, bleomycin, cactinomycin, calicheamicin, carabicin, carminomicin, carzinophilin, chromomycin, actinomycin D, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (Adriamycin), mycin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycin, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptozocin, tuberculin, ubenamide ubenimex, zinostatin, zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauracil glycosides, carmofur, cytarabine, dideoxyuridine, doceflurane, enocitabine, floxuridine, 5-FU; androgens such as captestosterone, dromostanolonepropionate, epitiostanol, mepitiostane, testolactone; antiadrenal agents such as aminoglutethimide, mitotane, trilostane; folic acid supplements such as frolinic acid; aceglucuronolide; aldophosphamide glycoside;aminolevulinic acid, amsacrine, bestrabucil, biasntrene, edatraxate, defofamine, colchicine, diaziquone, elfornithine, elliptinium acetate, etoglucid, gallium nitrate, hydroxyurea, lentinan, lonidamine, mitoguazone, mitoxantrone, mopidamol, nitracrine, pintostatin, phenamet, pirarubicin, podophyllinic acid acid); 2-ethylhydrazide; procarbazine; razoxane; sizotlran; spirogermanium; tricholorthosporic acid; triazoquinone; 2,2',2"-trichlorrotriethylamine; urethan; vindesine; dacarbazine; mannomustine; mitobronitol; dibromodulanol; pipobroman; gasytosine; arabinoside ("Ara-C"); thiotepa; taxoids, such as paclitaxel ( Bristol-Myers Squibb Oncology. Princeton. NJ) and docetaxel ( Rorer, Antony, France); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinblastine; vinorelbine; navelbine elbine; novantrone; teniposide; daunorubicin; aminopterin; Xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS2000; difluoromethylornithine (DMFO); retinoic acid; esperamicins; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above substances. This definition also includes antihormonal agents that regulate or inhibit the effects of hormones on tumors, such as antiestrogens, including, for example, tamoxifen, raloxifene, aromatase inhibitor 4 (5) -imidazole, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone and toremifene; antiandrogens such as flutamide, nilutamide, bicalutamide, leuprolide and goserelin; other chemotherapeutic agents such as prednisolone. Pharmaceutically acceptable salts, acids or derivatives of any of the above substances are included.
[0088] A detectable moiety is a compound or composition that can be conjugated directly or indirectly to the antibody. The label itself can be detectable alone (e.g., radioisotope labels or fluorescent labels), or in the case of an enzyme label, can catalyze chemical alteration of a substrate compound or composition that is detectable.
[0089] The terms "full length antibody," "intact antibody," and "whole antibody" are used interchangeably herein to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.
[0090] As used herein and as well understood in the art, the term "treating" or "treatment" means a method of obtaining a beneficial or desired result (including a clinical result). A beneficial or desired clinical result may include, but is not limited to, alleviating or improving one or more symptoms or conditions, reducing the extent of the disease, stabilizing (i.e., not worsening) the disease state, delaying or slowing disease progression, improving or alleviating the disease state, reducing disease recurrence, and alleviating (whether partially or completely), whether detectable or undetectable. "Treatment" and "treatment" may also mean prolonging survival compared to the expected survival if not receiving treatment. In addition to being useful as a method of treatment, the methods described herein may also be used for prevention or prophylaxis of a disease.
[0091] The term "pharmaceutical formulation" refers to a preparation that is in a form that permits the biological activity of the active ingredient contained therein to be effective, and which contains no additional components that are unacceptably toxic to a subject to which the formulation would be administered.
[0092] As used herein, the term "pharmaceutically acceptable" refers to solvents, cosolvents, surfactants, carriers, diluents, excipients, buffers, salts, solvates, hydrates and / or other components that are compatible with the other ingredients of the formulation and harmless to its recipient. "Pharmaceutically acceptable carrier" refers to ingredients other than the active ingredient in a pharmaceutical formulation that is non-toxic to the subject. Pharmaceutically acceptable carriers may include, but are not limited to, one or more of solvents, cosolvents, surfactants, diluents, buffers, excipients, stabilizers or preservatives.
[0093] As used herein, "buffering agent" refers to a buffer that resists pH changes by the action of its acid-base conjugate component. Buffering agent may be present in a liquid or solid formulation of the present invention. The pH of the formulation is adjusted by the buffering agent to about 5.0 to about 8.5, to about 5.5 to about 7.5, to about 6.0 to about 6.5, or to about 6.3 pH. In one aspect, the example of the buffering agent controlled in the range of pH 5.0 to 7.5 includes acetate, succinate, gluconate, histidine, tartrate, TRIS, citrate, phosphate, maleate, cacodylate, 2-[N-morpholino] ethanesulfonic acid (MES), bis(2-hydroxyethyl) iminotris[hydroxymethyl]methane (Bis-Tris), N-[2-acetylamino]-2-iminodiacetic acid (ADA), glycylglycine and other organic acid buffers. On the other hand, the buffering agent herein is histidine or citrate.
[0094] The term "sugar" as used herein refers to sugars having the general formula (CH 2 O)n Compounds and derivatives thereof, including monosaccharides, disaccharides, trisaccharides, polysaccharides, sugar alcohols, reducing sugars, non-reducing sugars, etc. In one aspect, the example of saccharide herein includes glucose, sucrose, trehalose, lactose, fructose, maltose, dextran, erythritol, glycerol, arabitol, xylitol, sorbitol, mannitol, melibiose, melezitose, raffinose, mannotriose, stachyose, maltose, lactulose, maltulose, glucitol, maltitol, lactitol, isomaltulose, etc. Sugar can be a lyophilizing protective agent. On the other hand, sugar herein is a non-reducing disaccharide, such as sucrose.
[0095] The term "surfactant" as used herein refers to an agent that reduces the surface tension of a liquid. The surfactant may be a nonionic surfactant. In one aspect, examples of surfactants herein include polysorbates (polyoxyethylene sorbitan monolaurate, such as polysorbate 20 and polysorbate 80); TRITON (tert-octylphenoxypolyethoxyethanol, a nonionic detergent, Union Carbide subsidiary of Dow Chemical Co., Midland Mich.); sodium dodecyl sulfate (SDS); sodium lauryl sulfate; sodium octyl glucoside; lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl-, or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauroyl-, cocamidopropyl-, linoleyl-, myristamidopropyl-, palmitamidopropyl-, or isostearamidopropyl-betaine (e.g., lauroyl); myristamidopropyl-, palmitamidopropyl-, or isostearamidopropyl-dimethylamine; sodium methyl cocoyl taurate or disodium methyl oleoyl taurate; sorbitan monopalmitate; and the MONAQUAT series (Mona Industries, Inc., Paterson, NJ); polyethylene glycol (PEG), polypropylene glycol (PPG), and copolymers of polyoxyethylene and polyoxypropylene glycol (e.g., Pluronics / Poloxamer, PF68, etc.); etc. In another aspect, the surfactant is polysorbate 80.
[0096] "Lyophilized" or "freeze-dried" means freeze drying, which is generally used to preserve proteins by removing water from a protein preparation of interest. Freeze drying or lyophilization is a process in which the material to be dried is first frozen and then the ice or frozen solvent is removed by sublimation in a vacuum environment. One or more excipients may be included in the pre-lyophilized formulation to enhance stability during the freeze drying process and / or to improve the stability of the lyophilized product upon storage.
[0097] A "reconstituted" formulation is one that is prepared by dissolving a lyophilized protein formulation in a carrier or diluent such that the protein is dispersed in the reconstituted formulation. The reconstituted formulation is suitable for administration (eg, parenteral administration) to the patient to be treated.
[0098] "Lyophilization protectants" are molecules that, when combined with a protein of interest, significantly prevent or reduce the chemical and / or physical instability of the protein during freeze-drying and subsequent storage. Exemplary lyophilization protectants include sugars / sugars, such as sucrose or trehalose; amino acids, such as sodium glutamate or sodium histidine; methylamines, such as betaine; lyotropic salts, such as magnesium sulfate; polyols, such as trivalent or higher sugar alcohols, such as glycerol, erythritol, glycerol, arabitol, xylitol, sorbitol, and mannitol; propylene glycol; polyethylene glycol; pluronics; and combinations thereof. Lyophilization protectants can be non-reducing sugars, such as trehalose or sucrose. Lyophilization protectants can be added to pre-lyophilized formulations in a "lyophilization protective amount," which means that after the protein is freeze-dried in the presence of a freeze-dried amount of lyophilization protectant, the protein substantially maintains its physical and chemical stability and integrity during freeze-drying and storage.
[0099] The "carrier or diluent" of interest herein is a carrier or diluent that is pharmaceutically acceptable (safe and non-toxic to human administration) and can be used to prepare a reconstituted formulation. Exemplary diluents include sterile water, bacteriostatic water for injection (BWFI), pH buffered solutions (e.g., phosphate-buffered saline), sterile saline solution, Ringer's solution, or dextrose solution.
[0100] "Preservative" is a compound that can be added to a diluent to substantially reduce bacterial action in a reconstituted formulation, for example, thereby facilitating the production of a versatile reconstituted formulation. Examples of potential preservatives include octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride (a mixture of alkylbenzyldimethylammonium chlorides in which the alkyl group is a long-chain compound), and benzethonium chloride. Other types of preservatives include aromatic alcohols (such as phenol, butanol, and benzyl alcohol), alkyl parabens (such as methyl or propyl paraben), catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol.
[0101] "Bulking agents" are compounds that add mass to the lyophilized mixture and contribute to the physical structure of the lyophilized cake (e.g., facilitate the production of a substantially uniform lyophilized cake that maintains an open pore structure). Exemplary bulking agents include mannitol, glycine, polyethylene glycol, and sorbitol (xorbitol).
[0102] As used herein, the term "tonicity regulator" is intended to mean one or more compounds that can be used to adjust the tension of a liquid formulation. Suitable tension regulators include glycerol, lactose, mannitol, dextrose, sodium chloride, magnesium sulfate, magnesium chloride, sodium sulfate, sorbitol, trehalose, sucrose, raffinose, maltose and other tension regulators known to those skilled in the art or those of ordinary skill. In one embodiment, the tension of a liquid formulation is close to that of blood or plasma.
[0103] Unless specifically indicated otherwise, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., U. S. Pat. of Health and Human Services, “Sequence of Proteins of Immunological Interest” (1983).
[0104] Suitable host cells for cloning or expressing the DNA in the vectors herein are prokaryotes, yeast cells or higher eukaryotic cells. Prokaryotes suitable for this purpose include, but are not limited to, eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia, such as Escherichia coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, such as Salmonella typhimurium, Serratia, such as Serratia marcescens. marcescans, and Shigella, and Bacilli such as B. subtilis and B. licheniformis, Pseudomonas such as Pseudomonas aeruginosa, and Streptomyces. These examples are exemplary and non-restrictive.
[0105] In some aspects, full-length antibodies, antibody fragments, and antibody fusion proteins can be produced in bacteria, particularly when glycosylation and Fc effector functions are not required, such as when therapeutic antibodies are conjugated to cytotoxic agents (e.g., toxins) and the immunoconjugates themselves show effectiveness in tumor cell destruction. Full-length antibodies have a longer half-life in circulation. After expression, the antibody is isolated from the E. coli cell paste as a soluble fraction and can be purified by, for example, a protein A or G column, depending on the isotype. Final purification can be performed similarly to the process used to purify antibodies expressed, for example, in CHO cells.
[0106] In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are suitable cloning or expression hosts. Many other genera, species and strains are generally available and useful herein, such as Saccharomyces cerevisiae, Schizosaccharomyces pombe; Kluyveromyces hosts, such as K. lactis, K. fragilis (ATCC 12,424), K. bulgaricus (ATCC 16,045), K. wickeramii (ATCC 24,178), K. waltii (ATCC 56,500), K. drosophilarum (ATCC 36,906), K. thermotolerans, and K. marxianus; Yarrowia (EP 402,226); Pichia pastoris (EP 183,070); Candida; Trichoderma reesia (EP 244,234); Neurospora crassa; Schwanniomyces such as Schwanniomyces occidentalis; and filamentous fungi such as, for example, Neurospora, Penicillium, Tolypocladium, and Aspergillus hosts such as A. nidulans and A. niger.
[0107] Examples of useful mammalian host cell lines are: monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL1651); human embryonic kidney line (293 / 293T or 293 cells subcloned to grow in suspension culture); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells (CHO); mouse Sertoli cells; monkey kidney cells (CV1 ATCC CCL70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human hepatocytes (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells; MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2).
[0108] Host cells are transformed with the above-described expression or cloning vectors and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
[0109] In some aspects, the antibody or antigen-binding fragment thereof antagonizes the interaction between ILT4 and HLA-G or HLA-A. In certain embodiments, the antibody or antigen-binding fragment thereof selectively binds to ILT4 relative to other leukocyte immunoglobulin-like receptor family members (e.g., ILT1, ILT2, ILT3, ILT5, ILT6, and / or ILT7). In some embodiments, the antibody or antigen-binding fragment thereof binds to human ILT4 with an affinity that is 2-100,000 times higher, or at least 2, 3, 5, 10, 20, 30, 40, 50, 60, 100, 500, 1000, 5000, 10,000, 13,000, 14,000, 15,000, 20,000, 50,000, or 100,000 times higher than the affinity that the antibody or antigen-binding fragment thereof binds to each of human ILT3 and human ILT2. In some embodiments, the antibody or antigen-binding fragment thereof does not cross-react with other ILT(LILR) family members as measured using surface plasmon resonance.
[0110] In some embodiments, the antibody or antigen-binding fragment thereof selectively binds to HLA-G, but not to one or more of MHC-I, AngptI, Nogo66, MAG, OMgp, β-amyloid protein, Sema4A, CD1c / d, and CSP. In some embodiments, the antibody or antigen-binding fragment thereof blocks the binding of ILT4 to HLA-A and / or HLA-G.
[0111] In some embodiments, the antibody or antigen-binding fragment thereof has an equilibrium dissociation constant (K) of less than or equal to 1 μM, less than or equal to 1 nM. D ) binds to ILT4. In some embodiments, the antibody or antigen-binding fragment thereof has an equilibrium dissociation constant (K) of 0.10 nM to 1 nM. D ) binds to ILT4. In some embodiments, the antibody or antigen-binding fragment thereof binds to ILT4 with an equilibrium dissociation constant (K) of less than 0.25 nM. D ) binds to ILT4. In some embodiments, the antibody or antigen-binding fragment thereof has an equilibrium dissociation constant (K D ) binds to ILT4: less than or equal to 1 nM, less than or equal to 0.9 nM, less than or equal to 0.8 nM, less than or equal to 0.7 nM, less than or equal to 0.6 nM, less than or equal to 0.5 nM, less than or equal to 0.4 nM, less than or equal to 0.3 nM, less than or equal to 0.2 nM, less than or equal to 0.1 nM, less than or equal to 0.09 nM, or less than or equal to 0.8 nM, less than or equal to 0.7 nM, less than or equal to 0.6 nM, less than or equal to 0.5 nM In some embodiments, the antibody or antigen-binding fragment thereof has an equilibrium dissociation constant (K) of less than or equal to 0.4 nM, less than or equal to 0.3 nM, less than or equal to 0.2 nM, less than or equal to 0.1 nM, less than or equal to 0.09 nM, or less than or equal to 0.07 nM, less than or equal to 0.07 nM, or less than or equal to 0.06 nM, less than or equal to 0.05 nM, or less than or equal to 0.04 nM, less than or equal to 0.03 nM, or less than or equal to 0.02 nM, less than or equal to 0.01 nM, or less than or equal to 0.008 nM. ... D ) binds to ILT4: 0.5 to 10 pM, 1 to 9 pM, 2 to 8 pM, 3 to 7 pM, or about 1 pM, about 2 pM, about 3 pM, about 4 pM, about 5 pM, about 6 pM, about 7 pM, about 8 pM, about 9 pM, or about 10 pM.
[0112] In some embodiments, the antibody or antigen-binding fragment thereof inhibits HLA-G with a potency of about 0.05 to about 0.50 μg / ml, or about 0.10 to about 0.25 μg / mL. In some embodiments, the antibody or antigen-binding fragment thereof inhibits HLA-G with a potency of less than 0.100 μg / ml.
[0113] In some embodiments, the antibody or antigen-binding fragment thereof inhibits HLA-A with a potency of about 0.05 to about 0.50 μg / ml, or about 0.10 to about 0.20 μg / mL. In some embodiments, the antibody or antigen-binding fragment thereof inhibits HLA-A with a potency of less than 0.10 μg / ml.
[0114] In some embodiments, the antibody or antigen-binding fragment thereof activates TNF-α production with a potency of about 7 ng / mL to about 25 ng / mL or about 12 ng / mL to about 20 ng / mL.
[0115] In some embodiments, the antibody or antigen-binding fragment thereof activates IL-6 production with a potency of about 5 ng / mL to about 25 ng / mL, about 6 ng / mL to about 22 ng / mL, or about 8 ng / mL to about 21 ng / mL.
[0116] In some embodiments, the antibody comprises a heavy chain constant region selected from the group consisting of IgG1, IgG2, IgG3, or IgG4; and the antibody comprises a light chain constant region selected from the group consisting of κ and λ.
[0117] In another aspect, the polypeptide can exhibit reduced affinity for at least one receptor (eg, FcγI, FcγIIA, or C1q) compared to a polypeptide comprising a wild-type human IgG Fc region.
[0118] In another aspect, the polypeptide comprises a human IgGl, IgG2, IgG3, IgG4, IgA, IgE or IgM Fc region.
[0119] In yet another aspect, the polypeptide comprises a human IgG1, IgG2 or IgG4 Fc region.
[0120] In some embodiments, the antibody or antigen-binding fragment thereof comprises one or more Fc domains, such as a pair of human Fc domains. In some embodiments, the human Fc domain is a human IgG1 Fc domain, a human IgG2 Fc domain, a human IgG3 Fc domain, or a human IgG4 Fc domain. In some embodiments, the human Fc domain is a human IgG4 Fc domain. In some embodiments, each of the human Fc domains comprises a sequence that is at least 80% identical to SEQ ID NO: 81. In some embodiments, each of the human Fc domains comprises a sequence that is at least 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 81. In some embodiments, the human Fc domain comprises SEQ ID NO: 81. In some embodiments, the human Fc domain comprises mutations for eliminating glycosylation and / or for reducing Fc-γ receptor binding. In some embodiments, the human Fc domain comprises mutations N297Q, N297A or N297G; in some embodiments, the human Fc domain comprises mutations at positions 234 and / or 235, such as L235E, or L234A and L235A (in IgG1), or F234A and L235A (in IgG4); in some embodiments, the human Fc domain is an IgG2 Fc domain comprising mutations V234A, G237A, P238S, H268Q / A, V309L, A330S or P331S or a combination thereof (all according to Kabat, EU numbering). In some embodiments, the human Fc domains each comprise a human IgG1 constant region mutation L234A / L235A ("LALA") or a human IgG1 constant region mutation L234A / L235A / P329G ("LALAPG"). Non-limiting examples of such mutations are provided in SEQ ID NOs:93 and 94.
[0121] Additional examples of engineered human Fc domains are known to those skilled in the art. The example of the Ig heavy chain constant region amino acid whose mutation causes Fc function reduction includes but is not limited to the mutation of amino acid 228, 233, 234, 235, 236, 237, 239, 252, 254, 256, 265, 270, 297, 318, 320, 322, 327, 329, 330 and 331 (according to Kabat, EU numbering) of heavy constant region. The example of the combination of the amino acid of mutation is also known in the art, such as but not limited to the combination of the mutation of amino acid 234, 235 and 331, such as 234, 235 and 329 (such as L234F, L235E and P331S), or the combination of amino acid 318, 320 and 322 (such as E318A, K320A and K322A).
[0122] Further examples of engineered Fc domains include F243L / R292P / Y300L / V305I / P396 IgG1; S239D / I332E IgG1; S239D / I332E / A330L IgG1; S298A / E333A / K334A; L234Y / L235Q / G236W / S239M / H268D / D270E / S298A IgG1 in one heavy chain, and D270E / K326D, A330M / K334E IgG in the opposite heavy chain; G236A / S239D / I332E IgG1; K326W / E333S IgG1; S267E / H268F / S324T IgG1; E345R / E430G / S440Y IgG1; N297A or N297Q or N297G IgG1; L235E IgG1; L234A / L235A IgG1; F234A / L235A IgG4; H268Q / V309L / A330S / P331S IgG2; V234A / G237A / P238S / H268A / V309L / A330S / P331S IgG2; M252Y / S254T / T256E IgG1; M428L / N434S IgG1; S267E / L328F IgG1; N325S / L328F IgG1, etc. In some embodiments, the engineered Fc domain comprises one or more substitutions selected from the group consisting of N297A IgG1, N297Q IgG1, and S228P IgG4.
[0123] In one aspect, polypeptides of the present disclosure comprising Fc variants exhibit reduced affinity for Fc receptors (e.g., FcγRI, FcγRIIA, FcγRIIIA) relative to unmodified antibodies. In one aspect, polypeptides comprising Fc variants exhibit affinity for Fc receptors that is at least 95%, at least 90%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40%, at least 30%, at least 20%, at least 10%, at least 5%, or at least 1% lower than wild-type polypeptides.
[0124] In one aspect, a polypeptide comprising an Fc variant of the disclosure exhibits greater than a 700-fold reduction in Fcγ binding, or greater than a 3,500-fold reduction in Fcγ binding.
[0125] In some embodiments, the antibody or its antigen-binding fragment comprises a variant Fc region of IgG1, IgG2, IgG3, IgG4, IgA, IgE or IgM. In certain embodiments, the antibody is a non-glycosylated antibody with reduced effector function. In certain embodiments, the variant Fc region of IgG1 comprises (a) an amino acid substitution at position Leu234 with alanine; (b) an amino acid substitution at position Leu235 with alanine; (c) an amino acid substitution at position Pro329 with glycine or arginine; (d) an amino acid substitution at position Asn297 with alanine; (e) an amino acid substitution at position Asn297 with glutamine; (f) an amino acid substitution at position Asn297 with glycine; or (g) any combination of (a) to (f). In certain embodiments, the variant Fc region of IgG2 comprises (g) an amino acid substitution at position Ser228 with proline; (h) an amino acid substitution at position Pro329 with glycine or arginine; or (i) both (g) and (h). In certain embodiments, the variant Fc region of IgG4 comprises (j) an amino acid substitution at position Ser228 with proline; (k) an amino acid substitution at position Leu235 with alanine or glutamic acid; (l) an amino acid substitution at position Pro329 with glycine or arginine; or (m) Any combination of (j) to (l).
[0126] The present disclosure also relates to immunoconjugates. In some embodiments, the antibody or antigen-binding fragment thereof is coupled to a chemotherapeutic agent, a cytotoxin, a detectable moiety, a diagnostic agent, or a combination thereof. In other embodiments, the antibody or antigen-binding fragment thereof is administered alone with a chemotherapeutic agent, a cytotoxin, a detectable moiety, a diagnostic agent, or a combination thereof.
[0127] The present invention also relates to an expression system and a host cell comprising the expression system. The expression system comprises at least one expression vector, including, for example, two or more, or three or more expression vectors. It will be readily understood by those of ordinary skill in the art that single or multiple expression vectors can be integrated into suitable host cells using conventional methods, including but not limited to transformation, transfection or viral infection. The expression system may comprise one or more nucleic acid sequences encoding proteins comprising antibodies or antigen-binding fragments thereof that bind to ILT4. One or more polypeptide chains constituting a fully formed antibody or antigen-binding fragment thereof that binds to ILT4 may each be expressed by a single vector, or may be expressed separately by two or more vectors in a host cell. For example, the heavy chain and light chain that together constitute the antibody or antigen-binding fragment thereof may be expressed by the same vector, or may be expressed by separate vectors.
[0128] The present disclosure also relates to a method for making the antibody or its antigen-binding fragment, which comprises culturing a host cell comprising an expression system under conditions that allow the formation of an antibody or its antigen-binding fragment that binds to ILT4, and a step of recovering the antibody or its antigen-binding fragment that binds to ILT4. In some embodiments, the method further comprises purifying the recovered antibody or its antigen-binding fragment that binds to ILT4.
[0129] The present disclosure also relates to a composition or preparation comprising an antibody or its antigen-binding fragment and a carrier that binds to ILT4, in some aspects, the carrier includes a pharmaceutically acceptable carrier or a diagnostic carrier. In some embodiments, the pharmaceutical composition may include an additional therapeutic agent. In some embodiments, the additional therapeutic agent is an antagonist of PD-1 / PD-L1, TIGIT or CTLA4. In certain embodiments, the antagonist of PD-L / PD-1 is selected from the group consisting of nivolumab, pembrolizumab, atezolizumab, durvalumab, lambrolizumab, avelumab and toripalimab. In some aspects, the antagonist of PD-L / PD-1 is toripalimab. The additional therapeutic agent can be, for example, a chemotherapeutic agent or a biotherapeutic agent (including but not limited to an antibody or antigen-binding fragment thereof that specifically binds to an antigen selected from the group consisting of PD-L1, PD-L2, CTLA4, BTLA, TIM3, HVEM, GITR, CD27, SIRPα, NKG2A, NKG2C, NKG2E, TSLP, IL10, VISTA, VEGF, EGFR, Her2 / neu, VEGF receptor, other growth factor receptors, CD20, CD28, CD40, CD-40L, CD70, CD73, CCR8, OX-40, 4-1BB and ICOS). The additional therapeutic agent may be selected from the group consisting of: a STING agonist, a poly ADP ribose polymerase (PARP) inhibitor, a mitogen-activated protein kinase (MEK) inhibitor, a cyclin-dependent kinase (CDK) inhibitor, an indoleamine 2,3-dioxygenase (IDO) inhibitor, a tryptophan 2,3-dioxygenase (TDO) selective inhibitor, an antiviral compound, an antigen, an adjuvant, an anticancer agent, a CTLA-4 pathway antagonist, a lipid, a liposome, a peptide, a cytotoxic agent, a chemotherapeutic agent, an immunomodulatory cell line, a checkpoint inhibitor, a vascular endothelial growth factor (VEGF) receptor inhibitor, a topoisomerase II inhibitor, a smoothened inhibitor, an alkylating agent, an antitumor antibiotic, an antimetabolite, a retinoid, and an immunomodulator (including but not limited to an anticancer vaccine).
[0130] In some embodiments, the pharmaceutical composition or formulation relates to a liquid formulation of an antibody or antigen-binding fragment thereof that binds to ILT4. In another further aspect, the disclosure relates to a lyophilized formulation comprising a mixture of an antibody or antigen-binding fragment thereof that binds to ILT4 and one or more excipients. In certain embodiments, the formulation may further include, but is not limited to, one or more of a buffer, a tension regulator, a surfactant, a lyoprotectant, a preservative, or a bulking agent.
[0131] The antibodies or antigen-binding fragments thereof that bind to ILT4 in the formulations of the present disclosure can have a given concentration, including, for example, in the range of 1 mg / ml to 200 mg / ml, or a concentration of at least about 1 mg / mL, at least about 10 mg / mL, at least about 50 mg / mL, at least about 100 mg / mL, at least about 150 mg / mL, at least about 200 mg / mL, or less than 200 mg / ml, or less than 100 mg / ml, or less than 50 mg / ml.
[0132] The present disclosure relates to a method of delivering an antibody or an antigen-binding fragment thereof that binds to ILT4 to a subject, comprising administering the antibody or the antigen-binding fragment thereof to the subject via a route of administration selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intraarticular, intrabronchial, intraperitoneal, intracapsular, intracartilaginous, intracavitary, intracavitary, intracerebellar, intraventricular, intracolonic, intracervical, intragastric, intrahepatic, intramyocardial, intraosseous, intrapelvic, intrapericardial, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrathecal, intra-Ommaya, intravitreal, intraocular, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.
[0133] The present disclosure includes methods for administering an antibody or an antigen-binding fragment thereof by introducing it into the body of a subject. For example, the method includes piercing the body of the subject with a needle of a syringe, a patch, a pen, an on-body syringe, or other injection device, and injecting the antibody or fragment into the body of the subject, such as into a vein, an artery, a tumor, a muscle tissue, or a subcutaneous tissue of the subject. For example, the injection device can be a syringe (e.g., a syringe pre-filled with a pharmaceutical composition, such as an automatic syringe), the syringe, for example, including a cylinder or barrel for accommodating a fluid to be injected (e.g., a fluid containing the antibody or fragment or its pharmaceutical composition), a needle for piercing the skin and / or a blood vessel to inject the fluid; and a plunger for pushing the fluid out of the cylinder and through the needle hole. In one embodiment of the invention, the injection device comprising the antibody or antigen-binding fragment thereof of the present invention or its pharmaceutical composition is an intravenous (IV) injection device. Such a device comprises the antibody or fragment or a pharmaceutical composition thereof in a cannula or trocar / needle that is attachable to a tube that is attachable to a fluid (e.g., saline; or a fluid containing NaCl, sodium lactate, KCl, CaCl) that is introduced into the body of the subject through the cannula or trocar / needle. 2 The invention provides a container (e.g., a plastic or glass vial, e.g., a plastic or glass vial with a cap or a chromatography column, a hollow bore needle or a syringe barrel) comprising any of the antibodies or antigen-binding fragments described herein or a pharmaceutical composition thereof comprising a pharmaceutically acceptable carrier.
[0134] In some embodiments, the cancer is squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, glioma, mesothelioma, gastrointestinal cancer, kidney cancer (e.g., clear cell carcinoma), ovarian cancer, liver cancer, colorectal cancer, endometrial cancer, kidney cancer (e.g., renal cell carcinoma (RCC)), prostate cancer (e.g., hormone-refractory prostate adenocarcinoma), thyroid cancer, neuroblastoma, pancreatic cancer, glioblastoma (glioblastoma multiforme), cervical cancer, stomach cancer, bladder cancer, hepatoma, breast cancer, colon cancer, head and neck cancer (or carcinoma), stomach cancer, germ cell tumors, childhood sarcomas, sinonasal natural killer cells, melanoma (e.g., metastatic malignant melanoma, such as skin or intraocular malignant melanoma), bone cancer, skin cancer, uterine cancer, cancer of the anal region, testicular cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, esophageal cancer, small intestine cancer, endocrine system cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, solid tumors in children, ureteral cancer, renal pelvis cancer, central nervous system (CNS) neoplasms, primary CNS lymphoma, tumor angiogenesis, spinal tumors, brain cancer, brain stem glioma, pituitary adenoma , Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, environmentally induced cancers (including cancers induced by asbestos), virus-related cancers or cancers of viral origin (e.g., human papillomavirus (HPV-associated or HPV-derived tumors)), and hematological malignancies arising from one of the two major blood cell lineages, the myeloid cell lineage (which produces granulocytes, erythrocytes, thrombocytes, macrophages and mast cells) or the lymphoid cell lineage (which produces B, T, NK and plasma cells), such as all types of leukemias, lymphomas and myelomas, e.g., acute, chronic, lymphocytic and / or myeloid leukemias diseases, such as acute leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML), undifferentiated AML (MO), myeloblastic leukemia (M1), myeloblastic leukemia (M2; with cell maturation), promyelocytic leukemia (M3 or M3 variant [M3V]), myelomonocytic leukemia (M4 or M4 variant with eosinophilia [M4E]), monocytic leukemia (M5), erythroleukemia (M6), megakaryoblastic leukemia (M7), solitary granulocytic sarcoma and chloroma;Lymphoma, such as Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), B-cell hematologic malignancies, e.g., B-cell lymphoma, T-cell lymphoma, lymphoplasmacytoid lymphoma, monocytoid B-cell lymphoma, mucosa-associated lymphoid tissue (MALT) lymphoma, anaplastic (e.g., Ki 1+) Large Cell Lymphoma, Adult T-Cell Lymphoma / Leukemia, Mantle Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Angiocentric Lymphoma, Intestinal T-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma, Precursor T-Lymphoblastic Lymphoma, T-Lymphoblastic; and Lymphoma / Leukemia (T-Lbly / T-ALL), Peripheral T-Cell Lymphoma, Lymphoblastic Lymphoma, Post-Transplant Lymphoproliferative Disorder, True Histiocytic Lymphoma, Primary Central Nervous System Lymphoma, Primary Effusion Lymphoma, B-Cell Lymphoma, Lymphoblastic Lymphoma ( LBL), hematopoietic neoplasms of the lymphoid lineage, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, Burkitt's lymphoma, follicular lymphoma, diffuse histiocytic lymphoma (DHL), immunoblastic large cell lymphoma, precursor B lymphoblastic lymphoma, cutaneous T-cell lymphoma (CTLC) (also known as mycosis fungoides or Sezary syndrome), and lymphoplasmacytoid lymphoma (LPL) with Waldenstrom's macroglobulinemia; myelomas, such as IgG myeloma, light chain myeloma, non- secretory myeloma, smoldering myeloma (also called indolent myeloma), solitary plasmacytoma and multiple myeloma, chronic lymphocytic leukemia (CLL), hairy cell lymphoma; hematopoietic tumors of the myeloid lineage, tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; seminoma, teratoma, central and peripheral nerve tumors, including astrocytoma, rhabdomyosarcoma, and osteosarcoma; and other tumors, including melanoma, xeroderma pigmentosum, keratoacanthoma, seminoma, fibrosarcoma, rhabdomyosarcoma, and osteosarcoma. thyroid follicular carcinoma and teratocarcinoma, hematopoietic tumors of the lymphoid lineage, such as T-cell and B-cell tumors, including but not limited to T-cell disorders such as T-prolymphocytic leukemia (T-PLL), including small cell and brain-like cell types; large granular lymphocytic leukemia (LGL) of T-cell type; a / dT-NHL hepatosplenic lymphoma; peripheral / post-thymic T-cell lymphoma (polymorphic and immunoblastic subtypes); angiocentric (nasal) T-cell lymphoma; head and neck cancer, kidney cancer, colorectal cancer, thyroid cancer; acute myeloid lymphoma, or a combination or metastasis thereof. ;
[0135] In certain embodiments, cancer is a solid tumor. In another embodiment, cancer is a hematological cancer. In certain embodiments, cancer is metastatic. In some embodiments, cancer is recurrent. In other embodiments, cancer is refractory. In yet other embodiments, cancer is recurrent and refractory. In some embodiments, cancer is anaplastic astrocytoma, astrocytoma, bladder cancer, bone cancer, brain cancer, breast cancer (e.g., characterized by mutations in BRCA1 and / or BRCA2), carcinoid cancer, cervical cancer, chondrosarcoma, choroid plexus papilloma, colorectal cancer, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, gallbladder cancer, gastric cancer, glioblastoma, head and neck cancer, hepatoblastoma, hepatocellular carcinoma, idiopathic myelofibrosis, kidney cancer, leukemia, liver cancer, lung cancer (e.g., non-small cell lung cancer), lymphoma, medulloblastoma, melanoma In some embodiments, the cancer is a metastatic cancer, such as a Schwann cell tumor of the vestibular nerve, ...
[0136] In embodiments of the invention, the cancer is a myeloid-rich tumor (e.g., mesothelioma, renal cancer, lymphoma, sarcoma, melanoma, head and neck cancer, breast cancer, bladder cancer, gastric cancer, ovarian cancer, or thyroid cancer. Since ILT4 is primarily expressed by myeloid cells and granulocytes, and myeloid cell infiltration into tumors is often associated with a poor prognosis because the immunosuppressive effects of these cells can antagonize the anti-tumor response of T cells, treatment with the anti-ILT4 antibodies or antigen-binding fragments of the present disclosure will benefit subjects with high myeloid or immunosuppressive myeloid cell infiltration.
[0137] In certain embodiments, the cancer is lung cancer, liver cancer, NSCLC, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, pancreatic cancer, glioblastoma, glioma, kidney cancer, stomach cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, or head / neck cancer.
[0138] The present invention includes ELISA assays (enzyme-linked immunosorbent assays) incorporating the use of the antibodies or antigen-binding fragments thereof disclosed herein. For example, such a method for determining whether a sample contains ILT4 or a fragment thereof comprises the following steps:
[0139] (a) coating a substrate (e.g., a microtiter plate well, such as a surface of a plastic plate) with an anti-ILT4 antibody (e.g., a fully human antibody, such as an antagonistic fully human antibody) or an antigen-binding fragment thereof;
[0140] (b) applying a sample to be tested for the presence of ILT4 to a substrate;
[0141] (c) washing the substrate to remove unbound material from the sample;
[0142] (d) applying a detectably labeled antibody (eg, an enzyme-linked antibody) that is also specific for the ILT4 antigen;
[0143] (e) washing the substrate to remove unbound labeled antibody;
[0144] (f) detecting the label on the antibody; if the labeled antibody is enzyme-linked, applying a chemical substance that is converted by the enzyme into a detectable signal (e.g., a fluorescent signal); and
[0145] (g) Detecting a marker indicative of the presence of ILT4 protein (eg, a substrate-associated marker).
[0146] The present invention also includes surface plasmon resonance (SPR) assays incorporating the use of the antibodies or antigen-binding fragments thereof disclosed herein. In some aspects, the present disclosure includes evaluating antibody binding activity, affinity, and cross-reactivity, and includes the following steps:
[0147] (a) preparing one or more capture surfaces by immobilizing anti-Fc molecules on the one or more capture surfaces;
[0148] (b) flowing a solution comprising the anti-ILT4 antibody over the one or more capture surfaces to immobilize the anti-ILT4 on the one or more surfaces;
[0149] (c) flowing the analyte over the capture surface according to step (b) to measure the association of the analyte with the anti-ILT4 antibody; and
[0150] (d) flowing a buffer over the capture surface according to step (c) to measure the dissociation of the analyte from the anti-ILT4 antibody;
[0151] (e) passing a regeneration solution over the one or more capture surfaces of step (d) to remove any residual analyte / anti-ILT4 complexes or unbound anti-ILT4 antibodies from the surface.
[0152] The binding affinity can be determined by dividing the dissociation rate by the association rate. In some embodiments, one or more additional analytes may be included in flowing over the capture surface.
[0153] The present invention also includes a competitive binding assay between an ILT4 antibody and one or more analytes, comprising the following steps:
[0154] (a) preparing one or more capture surfaces by capturing a first ligand to the one or more capture surfaces;
[0155] (b) preparing a solution comprising an anti-ILT4 antibody and a second analyte;
[0156] (c) flowing a solution comprising the anti-ILT4 antibody and a second analyte over the capture surface prepared in step (a); and
[0157] (d) Measuring response.
[0158] In some embodiments, the capture surface can be activated according to the manufacturer's instructions, e.g., using EDC / NHS (N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide hydrochloride and N-hydroxysuccinimide (Biacore GE Healthcare), and deactivated, e.g., using ethanolamine (Biacore GE Healthcare). In some embodiments, the capture surface is coated with, e.g., avidin, streptavidin, neutravidin, or a derivative thereof to immobilize the biotinylating agent.
[0159] In one embodiment of the invention, the labeled antibody or antigen-binding fragment thereof is labeled with a peroxidase that reacts with ABTS (e.g., 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)) or 3,3′,5,5′-tetramethylbenzidine to produce a detectable color change. Alternatively, the labeled antibody or fragment is labeled with a detectable radioisotope (e.g., 3 H) labeling, which isotope can be detected by a scintillation counter in the presence of a scintillant.
[0160] The anti-ILT4 antibodies (e.g., fully human antibodies, such as antagonistic fully human antibodies) or antigen-binding fragments thereof of the present invention can be used in a protein blotting or immunoprotein blotting procedure. Such procedures form part of the present invention and include, for example: (1) providing a membrane or other solid substrate containing a sample to be tested for the presence of ILT4 or a fragment thereof, which, for example, optionally includes the following steps: transferring proteins from the sample to be tested for the presence of ILT4 (e.g., proteins separated by PAGE or SDS-PAGE electrophoresis of proteins in the sample) to a membrane or other solid substrate (e.g., using methods known in the art (e.g., semi-dry blotting or slot blotting)); and contacting the membrane or other solid substrate to be tested for the presence of bound ILT4 or a fragment thereof with the anti-ILT4 antibodies or antigen-binding fragments thereof of the present invention; (2) washing the membrane one or more times to remove unbound anti-ILT4 antibodies or fragments and other unbound substances; and (3) detecting bound anti-ILT4 antibodies or fragments.
[0161] Such a membrane may take the form of, for example, a nitrocellulose or vinyl-based (e.g., polyvinylidene fluoride (PVDF)) membrane to which the protein to be tested for the presence of ILT4 in a native PAGE (polyacrylamide gel electrophoresis) gel or SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) gel has been transferred (e.g., after electrophoretic separation in the gel). Prior to contacting the membrane with the anti-ILT4 antibody or fragment, the membrane is optionally blocked, e.g., using skim milk powder, etc., in order to bind to nonspecific protein binding sites on the membrane.
[0162] Detection of bound anti-ILT4 antibody or fragment indicates the presence of ILT4 protein on the membrane or substrate and in the sample. Detection of bound antibody or fragment can be performed by combining the antibody or fragment with a detectably labeled secondary antibody (anti-immunoglobulin antibody) and then detecting the presence of the secondary antibody label.
[0163] Anti-ILT4 antibodies (e.g., fully human antibodies, such as antagonistic fully human antibodies) and antigen-binding fragments thereof disclosed herein can also be used for immunohistochemistry. Such methods constitute part of the present invention and include, for example, (1) contacting cells (e.g., myeloid lineage cells, such as monocytes, macrophages or dendritic cells) to be tested for the presence of ILT4 protein with an anti-ILT4 antibody or antigen-binding fragment thereof of the present invention; and (2) detecting the antibody or fragment on or in the cell.
[0164] If the antibody or fragment itself is detectably labeled, it can be detected directly. Alternatively, the antibody or fragment can be combined with a detectably labeled secondary antibody, where the label is then detected.
[0165] Example
[0166] The following examples are intended to illustrate the present disclosure, but not to limit the claimed invention. All molecules, compositions, methods, assays and results disclosed in the examples constitute part of the present invention.
[0167] Example 1
[0168] Production and selection of mouse anti-human immunoglobulin-like transcript 4 (ILT4) antibodies: Mice were immunized with human ILT4 and screened for high anti-ILT4 antibody titers. Hybridomas that produce antibodies that bind to ILT4 and block ILT4 / HLA-G interactions were initially screened using flow cytometry. Additional screening was performed to confirm binding to ILT4 and characterize ILT4 binding specificity. The antibodies selected after the secondary screening were purified and further tested for affinity to ILT4 and efficacy against ILT4 / HLA-G binding. Antibodies with the highest ILT4 affinity and ILT4 / HLA-G blocking activity from the secondary screening were selected as leads for further characterization and humanization. The antibodies selected from the secondary screening were confirmed to have the ability to block ILT4 binding to both HLA-G and HLA-A by flow cytometry and SPR.
[0169] Example 2
[0170] Antibody humanization: The design of humanized VH and VL amino acid sequences was performed as follows according to the procedure described in Tsurushita et al. (Tsurushita et al., 2005. Design of humanized antibodies: From anti-Tac to Zenapax. Methods 36: 69-83), which is incorporated herein by reference in its entirety. First, a three-dimensional molecular model of the variable region of a mouse monoclonal antibody (mouse mAb) was constructed. Second, the molecular model was used to predict the framework amino acid residues that are important for the formation of the CDR structure or necessary for antigen binding. At the same time, human VH and VL amino acid sequences derived from cDNAs that have high homology to the mouse mAb VH and VL amino acid sequences, respectively, were selected. Finally, the CDR sequences were transplanted from mouse mAb VH and VL into the corresponding selected human framework sequences together with the framework amino acid residues that are important for the formation of the antigen binding site.
[0171] Search for people's VH sequences homologous to mouse mAb VH framework in the GenBank database, and select the encoded VH sequence without somatic hypermutation in the framework as the acceptor for humanization.First, the CDR sequence of mouse mAb VH is transferred to the corresponding position of the VH from the GenBank sequence.Next, at the framework position where the three-dimensional model of mouse mAb variable region indicates significant contact with CDR, the amino acid residues from the VH of the GenBank sequence are replaced with the corresponding residues of mouse mAb VH.
[0172] Next, search for the human VL region sequence homologous to the mouse mAb VL framework sequence in the GenBank database, and select the encoded VL sequence without somatic hypermutation in the framework as the acceptor for humanization.First, the CDR sequence of mouse mAb VL is transferred to the corresponding position of GenBank VL.Next, at the framework position where the three-dimensional model of mouse mAb variable region indicates significant contact with CDR, the amino acid residue of GenBank VL is replaced with the corresponding residue of mouse mAb VL, just like the above-mentioned VH district.
[0173] Example 3
[0174] Mouse anti-human immunoglobulin-like transcript 4 (ILT4) antibody on macrophage repolarization: Known ILT4 antibodies were tested in a macrophage repolarization assay developed to confirm the activity of known ILT4 antibodies as controls. Human monocytes were differentiated into M2 macrophages for 6 days and then stimulated with lipopolysaccharide (LPS) and ILT4 antibodies to be assayed using ELISA.
[0175] Mouse anti-human immunoglobulin-like transcript 4 (ILT4) antibodies (L45S4, L77S2, L156S3, L161S and L180S4) and control antibodies (anti-KLH IgG4 negative control and control antibody J19h1 as positive control) were used in the human macrophage repolarization assay. The secreted cytokines were measured by Meso Scale Discovery (MSD) assay using an MSD plate reader (MESOSector S 600 from Meso Scale Diagnostics LLC) and flow cytometry analysis of cell surface proteins using a flow cytometer (Attune NXT from ThermoFisher) to measure macrophage repolarization. Macrophages of the inhibitory M2 phenotype derived from human monocytes were prepared by derivatization in the presence of M-CSF. These cells were stimulated with LPS and the phenotype was evaluated by MSD analysis and flow cytometry.
[0176] Generation of monocyte-derived macrophages: PBMCs were isolated from fresh buffy coats from two different blood donors using standard density centrifugation. Cells were resuspended in buffer and counted. Cell density was then adjusted to 5x10 in buffer. 7 Cells / mL. The isolated mononuclear cells from PBMCs were centrifuged and resuspended in culture medium. The density was adjusted to 0.5x10 cells / mL with 30 ml differentiation medium. 6 cells / ml and plated the cells. Three days later, half the volume of differentiation medium was added and the cells were cultured for another three days.
[0177] Macrophage stimulation and treatment with antibodies: Cells were plated using growth medium. Serial dilutions of the test antibodies were prepared in duplicate wells of the plate to obtain final concentrations ranging from 30 μg / ml to 0.03 ng / ml. Subsequently, LPS was added to a final concentration of 100 ng / ml.
[0178] Macrophage phenotype analysis: Human macrophages with a suppressive M2 phenotype were prepared and then stimulated with LPS in the presence of ILT4 antibody or control antibody. After 2 days of LPS stimulation in the presence of ILT4 antibody or control, the plates were centrifuged and the supernatants were collected for quantification of proinflammatory cytokines TNF-α and IL-6 by MSD analysis.
[0179] Mesoscale discovery assay for cytokine secretion: To determine the effect of mouse anti-human ILT4 antibodies on macrophage polarity, supernatants were analyzed by MSD. For both blood donors, all ILT4 antibodies increased TNF-α secretion compared to control ( Figure 1A and 1B ). The maximum effect ranged from a 4- to 5-fold increase compared to the anti-KLH IgG4 negative control. The control antibody increased TNF-α secretion 8-fold compared to the negative control.
[0180] For both donors, all ILT4 antibodies tested also increased IL-6 secretion by two-fold compared to the highest control concentration ( Figure 2A and 2B ). The control antibody increased the IL-6 secretion of donor A by 3-fold and that of donor B by 2-fold.
[0181] Flow cytometric analysis of surface marker expression of macrophages: Expression of cell surface proteins indicative of polarity was assessed by flow cytometry. Figure 3A and 3B ) and CD209( Figure 4A and 4B) of the staining. The ILT4 antibody did not induce the change of macrophage surface protein expression from M1-type proteins to M2-type proteins. This was observed in both the control antibody and the ILT4 antibody.
[0182] Similar to the control antibody, the ILT4 antibody increased the production of proinflammatory cytokines TNF-α and IL-6 in a dose-responsive manner. The results of the macrophage repolarization assay confirmed that the ILT4 antibody induced the repolarization of suppressive M2-type macrophages toward the proinflammatory M1 phenotype.
[0183] Example 4
[0184] The efficacy of mouse anti-human immunoglobulin-like transcript 4 (ILT4) antibody in blocking the interaction between human ILT4 and HLA-G: The ability of mouse anti-human immunoglobulin-like transcript 4 (ILT4) antibody to block the interaction between human ILT4 and HLA-G was tested. A commercially available non-HLA-G blocking antibody was included as a negative control. A control antibody was included as a positive control. Blocking activity was measured in a flow cytometry assay using soluble fluorescently conjugated HLA-G and a CHO-S / ILT4 cell line engineered to express human ILT4 on the surface. Parental CHO-S cells that do not express human ILT4 were used as controls.
[0185] Soluble fluorescent conjugated HLA-G and CHO-S / ILT4 cells were used to evaluate the ability of control and candidate mouse anti-human ILT4 antibodies to block the interaction between human ILT4 and HLA-G. Cells expressing human ILT4 were first pre-incubated with ILT4 antibodies and then incubated with HLA-G. Flow cytometry was then used to quantify the binding of HLA-G to cells. The resulting cell-associated fluorescence was quantified and used to calculate the efficacy of ILT-4 blocking.
[0186] CHO-S and CHO-S / ILT4 cultures: CHO-S cells were cultured in CD OptiCHO medium and CHO-S / ILT4 cells were cultured in OptiCHO medium containing 20 μg / ml puromycin at 5% carbon dioxide, 37 degrees Celsius with shaking at 150 revolutions per minute (RPM).
[0187] HLA-G titration in HLA-G binding assay: CHO-S parental cells and CHO-S / ILT4 cells were pelleted by centrifugation and washed at 200,000 cells / mL in FACS buffer (PBS + 0.5% bovine serum albumin (BSA)). Cells were resuspended at 1,000,000 cells / mL in fluorescence activated cell sorting (FACS) buffer, transferred to a 96-well round-bottom 96-well plate at 50,000 cells / well, and placed on ice. All subsequent operations were performed on ice.
[0188] Prepare a 50 μg / ml dilution of the primary tetramer in FACS buffer. In a separate 96-well plate, prepare a 1:2 serial dilution of the tetramer from 50 μg / ml to 0.05 μg / ml. Add 50 μl of each dilution to the cells in duplicate. Mix the wells and incubate at 4 degrees Celsius for 30 minutes. Wash the cells twice in FACS buffer and resuspend in 250 μl of FACS buffer containing 0.1 μg / ml propidium iodide.
[0189] Cells were collected on an Attune flow cytometer (5000 cells were collected for each sample) and mean fluorescence intensity (MFI) was recorded. MFI at different antibody concentrations was plotted using Prism software (Graphpad).
[0190] Antibody titration in HLA-G blocking assay: CHO-S / ILT4 cells were pelleted by centrifugation and washed at 200,000 cells / ml in FACS buffer (PBS + 0.5% BSA). Cells were resuspended in FACS buffer at 1,000,000 cells / ml, transferred to a 96-well round-bottom 96-well plate at 50,000 cells / well, and placed on ice. All subsequent operations were performed on ice.
[0191] In the first blocking experiment, negative control non-HLA-G blocking antibody 287219R (lot number: CMIF0221051, from R&D Systems, cat#MAB2078R) and positive control HLA-G blocking control antibodies J19h1 and 1E1 were evaluated. Primary antibody dilutions were prepared by diluting the antibody to 30 μg / ml in FACS buffer. Ten three-fold serial dilutions from 30 μg / ml to 0.001 μg / ml were then prepared in FACS buffer, and 50 μl was taken from each dilution and added to the cells in duplicate. The control wells received FACS buffer without antibodies. The wells were mixed and incubated at 4 degrees Celsius for 30 minutes. The cells were washed twice in FACS buffer.
[0192] In the second blocking experiment, the primary antibody dilution was prepared by diluting the antibody to 15 μg / ml in FACS buffer. Then three independent sets of eleven 2.5-fold serial dilutions from 15 μg / ml to 0.002 ug / ml were prepared in FACS buffer. Each dilution set was manipulated independently, and 50 μl was added to the cells from each dilution set in duplicate. The control wells received FACS buffer without antibody. The wells were mixed and incubated at 4 degrees Celsius for 30 minutes. The cells were washed twice in FACS buffer.
[0193] In both blocking experiments, phycoerythrin (PE)-conjugated HLA-G tetramers were diluted to 5 μg / ml in FACS buffer and added to cells at 100 ul per well. Cells were incubated at 4 degrees Celsius for 30 minutes, washed twice in FACS buffer, and resuspended in 250 μl of FACS buffer containing 0.1 μg / ml propidium iodide.
[0194] Cells were collected on an Attune flow cytometer (5000 propidium iodide-negative cells were collected for each sample) and the MFI was recorded. The relative blocking activity was calculated using the following formula: 100-(sample MFI-background MFI) / (top MFI-background MFI)*100. The MFI and relative blocking activity of each sample were plotted using Prism software (Graphpad). The blocking potency of each antibody was calculated using Prism software, which is expressed as IC 50 express.
[0195] HLA-G titration: Binding of PE-conjugated HLA-G to CHO-S parental cells and CHO-S / ILT4 cells was quantified by flow cytometry in the PE channel. HLA-G bound to CHO-S / ILT4 cells with a maximum MFI of 783-fold higher than untreated cells. Binding to parental CHO-S cells was lower with a maximum MFI of 43-fold higher than untreated cells ( Figure 5 ). Based on these figures, 5 μg / ml phycoerythrin-conjugated HLA-G was selected as the concentration for evaluating the ability of candidate antibodies to block the binding of HLA-G to CHO-S / ILT4 cells.
[0196] In the first experiment, preincubation with J19h1 and 1E1 reduced PE-HLA-G MFI by up to 22-fold and 30-fold, respectively, compared to cells treated with PE-HLA-G alone. Preincubation with the control antibody 287219R failed to reduce PE-HLA-GMFI. IC values for HLA-G blockade by J19h1 and 1E1 were 50 The values were all 0.13 μg / ml. The IC of the control antibody 287219R could not be calculated. 50Values (Table 1).
[0197] Table 1
[0198]
[0199] In the second experiment, the ILT4 antibody blocked the binding of HLA-G to CHO-S / ILT4 cells, as evidenced by a decrease in the MFI of PE-HLA-G on CHO-S / ILT4 cells. Figure 6 As a blocking agent for EC 50 (μg / ml) are shown. The extent of this reduction depended on the antibody, with L41S5 causing up to a 14-fold reduction and L45S4 causing up to a 69-fold reduction. IC 50 The values ranged from 0.044 μg / ml to 0.216 μg / ml (Table 2).
[0200] Table 2
[0201]
[0202]
[0203] The results showed that mouse anti-human ILT4 antibodies were able to block the interaction between soluble HLA-G and cell-expressed ILT4 in flow cytometry assays. The non-blocking antibody used as a negative control did not affect the HLA-G MFI on CHO-S / ILT4 cells, indicating that there was no blocking of the HLA-G / ILT4 interaction. The two control antibodies used as positive controls resulted in a decrease in the HLA-G MFI on CHO-S / ILT4 cells, indicating that the assay detected a blocking of the HLA-G / ILT4 interaction. Mouse anti-human ILT4 antibodies also blocked the HLA-G / ILT4 interaction. The effect on HLA-G MFI ranged from a 14-fold to a 69-fold reduction in MFI. The potency of mouse anti-human ILT4 antibodies ranged from 0.065 μg / ml to 0.171 μg / ml. Figure 7 An exemplary IC50 curve for ILT4 blockade from an HLA-G assay using flow cytometry is shown. Control antibodies 1E1 and J19h1 were included for comparison.
[0204] Example 5
[0205] Surface Plasmon Resonance (SPR) Analysis of Binding of Mouse, Chimeric and Humanized Anti-ILT4 Antibodies to ILTR4 (LILRB2): SPR was used to characterize the binding affinity and blocking of mouse, chimeric and humanized anti-ILT4 antibodies as described above to ILT4 (LILRB2).
[0206] Label-free SPR analysis on a Biacore T200 instrument was used to measure the affinity of antibodies for ILT4. All medium resolution analyses used CM4 sensor chips from Cytiva Inc. Anti-mouse Fc-specific or anti-human Fc-specific capture surfaces were prepared using standard amine coupling chemistry. Mouse, chimeric or humanized mAbs were captured to their respective surfaces and ILT4 from 101nM to 0.79nM in a 2-fold serial dilution series was injected across the surface at a flow rate of 100μL / min. Since medium resolution analysis was implemented here, the association phase was tracked for 90 seconds and the dissociation phase was tracked for 1200 seconds. The sensorgrams were double referenced and globally fitted to a 1:1 interaction model with terms incorporated for mass transfer, and the equilibrium dissociation constant was calculated as K D =k 解离(off) / k 缔合(on) The slowest k that can be measured can be reduced by 5% in the dissociation phase within 1200 seconds. 解离 is 4.27x10 -5 s -1 Therefore, if k is initially calculated from a global nonlinear fit of the data 解离 Slower than 4.27x10 -5 s -1 , then during the subsequent refitting in the global analysis, k 解离 will remain constant at 4.27x10 -5 s -1 All kinetic experiments were performed at 25°C in a buffer consisting of Hepes-buffered saline (pH 7.4) containing 0.05% polysorbate 20 (HBS-P+) and 100 μg / ml bovine serum albumin (BSA). Table 3 shows the results of all binding assays performed.
[0207] Table 3
[0208]
[0209] The values in bold and underlined represent k 解离 During the 20-minute dissociation process, it remained constant at its theoretical limit of 4.27x10 -5 s -1 .
[0210] High resolution binding kinetics of ILT4 binding using humanized anti-ILT4-LALA antibody were measured in triplicate and the results are summarized as follows (numbers in parentheses are 95% confidence intervals):
[0211]
[0212] The anti-ILT4 antibodies Hz45 and Hz156 were evaluated in a series of in vitro assays assessing: 1) binding to recombinant human and cynomolgus ILT4; 2) binding to ILT4-related molecules from the LILRA and LILRB families; and 3) the effect of binding to ILT4 on the inhibition of HLA-A and HLA-G binding to recombinant human ILT4.
[0213] Both antibodies bound tightly to ILT4, with a K of Hz45 D =154pM, Hz156K D =5.7pM. The association rates of these two antibodies were similar, both about 3.3x10 6 M -1 s -1 For ILT4, Hz45 had a 29-fold faster dissociation rate than Hz156, at 53.1 x 10 -5 s -1 , thus the weaker affinity of Hz45 is mainly due to the faster dissociation rate observed compared to Hz156.
[0214] Neither antibody molecule showed binding to recombinant cynomolgus monkey ILT4 nor to recombinant human LILRA1-6 and LILRB1-4 family members, except LILRB2 (ILT4). Antibodies Hz45 or Hz156 pre-complexed with recombinant human ILT4 blocked the binding of ILT4 to HLA-A and HLA-G.
[0215] All experiments described herein were performed using a Biacore T200 instrument at 25°C using a running buffer of Hepes-buffered saline, pH 7.4, 0.05% polysorbate 20 (HBS-P+) supplemented with 100 μg / mL bovine serum albumin (BSA). The running buffer used to immobilize the antibodies to the surface was HBS-P+ without added BSA.
[0216] Surface plasmon resonance spectroscopy was used to evaluate the binding between ILT4 and antibodies Hz45 and Hz156. The binding affinity of each antibody for ILT4 was measured, and both interactions exhibited fast association rate constants, but the dissociation rate constant of Hz156 was 29 times slower than that of Hz45. Antibodies Hz45 and Hz156 both exhibited strong affinities for ILT4 of 154pM and 5.7pM, respectively. Neither molecule showed binding to recombinant cynomolgus monkey ILT4, nor to recombinant human LILRA1-6 and LILRB1-4 family members, except LILRB2 (ILT4). Hz45 or Hz156 pre-complexed with recombinant human ILT4 blocked the binding of ILT4 to HLA-A and HLA-G.
[0217] Kinetic Exclusion Assay
[0218] Perform kinetic exclusion assay To measure the equilibrium binding affinity and kinetics between human ILT4 and four humanized LALA-Fc modified antibodies in solution. For affinity analysis, the equilibrium dissociation constant K D is determined experimentally and reflects the strength of the binding interaction. The association rate k 缔合 is also determined experimentally, and the dissociation rate k 解离 is calculated based on the following equation: 解离 =K D xk association
[0219] K D The analysis requires the immobilization of one interaction partner (the titrated binding partner) to a solid phase, which is then used as a probe to capture the other interaction partner, the constant binding partner (CBP). For each experiment, one of the binding partners is titrated against a background of CBP and allowed to reach equilibrium. The solution is then briefly exposed to the solid phase and a portion of the free CBP is captured. The captured CBP is then labeled with a fluorescent secondary molecule. The brief contact time with the solid phase is less than the time required for the pre-formed complex in the solution to dissociate, so competition between the titrated binding partner in the solution and the solid phase is "kinetically eliminated." Since the solid phase is used only as a probe for free CBP in each sample, the solution equilibrium does not change during the KinExA measurement.
[0220] The K is determined using the signal generated by the captured CBP, which is proportional to the concentration of free CBP in the sample at equilibrium. D KinExA Pro software performed least squares analysis on the measured data to fit the K value of 1:1 reversible bimolecular interaction. D The optimal solution of .
[0221] Determination of binding kinetics is done in a similar format to equilibrium analysis, except that measurements are collected "before equilibrium" and the binding signal is a function of time. Kinetic experiments are known as direct methods. This method keeps the titrated concentration and the concentration of CBP constant, and the solution is probed over time. As the sample approaches equilibrium, the amount of free CBP in solution will decrease.
[0222] The binding affinities (K) of four different humanized LALA IgG antibodies against ILT4 were measured using KinExA. D ), association (k 缔合 ) and the dissociation rate constant (k 解离The K of this interaction was determined using n-curve analysis of at least two different curves run at two different CBP concentrations. D。 ILT4 was used as the concentration reference for all curves. All binding systems had low errors and well-defined 95% confidence intervals, providing confidence in the measurements:
[0223]
[0224] ILT4 competitive binding studies between HLA-A and HLA-G and anti-ILT4 antibodies as probed by SPR: Four chimeric and humanized anti-ILT4 mAbs were probed for blocking LILRB2 binding to HLA-A (A*02:01; Immunitrack, Denmark) and HLA-G (monomeric HLA-G was prepared at Fred Hutchinson Cancer Center, Seattle, WA) using SPR spectroscopy on a Biacore T200 instrument. Neutravidin was immobilized to all four streams of a CM4 chip using standard amine coupling chemistry, and biotinylated HLA-G was captured on flow cell 2 and biotinylated HLA-A on flow cell 4, with flow cells 1 and 3 used as references, respectively. These competitive experiments were performed using a "pre-mix" format, in which 514 nM ILT4 was mixed with approximately 600 nM mAb binding sites. At these concentrations, for most of the antibodies studied, about 0.1% of the 514nM ILT4 in the solution will be free at equilibrium. The ILT4 / mAb complex was injected across all four sensor surfaces at 30μL / min in HBS-P+ buffer containing 100μg / mL BSA for 60 seconds. The dissociation phase was tracked for 60 seconds and all sensorgrams were double referenced. If a binding signal is observed for any given ILT4 / mAb complex, the mAb is designated as a non-competitive binder for ILT4 binding. In contrast, if no significant binding signal is observed for the binding of a specific ILT4 / mAb complex to captured HLA-A or HLA-G, the mAb is designated as a competitive binder for ILT4. All four chimeric and humanized mAbs studied are competitive binders for ILT4 to HLA-A and HLA-G.
[0225] SPR and flow-based characterization of the blocking activity of humanized (Hz) versions of L45S4, L77S2, L156S3 and L180S4 between ILT4 and HLA-G. Table 4 below shows the characterization of humanized ILT4 antibodies (numbers in brackets are 95% confidence intervals).
[0226] Table 4
[0227]
[0228] SPR cross-reactivity studies of four humanized anti-ILT4 antibodies with nine LILRA and LILRb homologs: Many LILRA and LILRB family members share high homology with LILRB2 (ILT4), as shown in Table 5. Therefore, determining the specificity and cross-reactivity profiles of humanized anti-ILT4 antibodies with other family members is critical to characterize the binding and functional properties of humanized anti-ILT4 mAbs.
[0229] SPR was used to determine the specificity of four humanized anti-ILT4 mAbs binding to LILRB2 and to determine any cross-reactions with the other nine LILRA and LILRB family members. LILR proteins were purchased from AcroBiosystems or R&D Systems, and their sequences are provided below. The study was performed using a Biacore 8K instrument using a CM4 sensor chip with a running buffer of HBS-P+, 100 μg / mL BSA. Anti-human Fc-specific capture surfaces were prepared using standard amine coupling chemistry. MAbs were captured to flow cell 2, and flow cell 1 was used as a reference flow cell. Each of the nine family members and LILRB2 were injected at 100 nM at 30 μL / min for 90 seconds and dissociated for 240 seconds. Cross-reactions were determined by examining sensorgrams that had significant binding signals in addition to showing the true molecular binding interaction shape. During data processing, all sensorgrams were double referenced. Table 5 shows the results from the cross-reaction study. MAbs 45_01, 77_01, and 156_03 did not cross-react with any family members and bound only to LILRB2. MAb 180_04 showed some cross-reactivity to family members LILRA1, LILRA3, and LILRB1. The results indicate that cross-reactivity with mAb 180_04 alone requires greater than 79% homology to LILRB2. The strongest cross-reactive binding interaction observed with mAb 180_04 was with LILRA3 and appeared to have a K in the range of 600-700 nM. D .
[0230] The above method was performed on Biacore T200 to determine whether any of these four mAbs cross-reacted with cynomolgus monkey LILRB2. No cross-reactivity was observed for any of these mAbs (Table 5).
[0231] Table 5
[0232]
[0233] - No binding
[0234] + / - Very weak binding (about mM K D )
[0235] + Weak binding (about 600-700nM K D )
[0236] +++Binding (1-2nM K D )
[0237] ++++Tightly bound (<100pM K D )
[0238] Example 6 - Blocking activity of humanized anti-ILT4 antibodies
[0239] To demonstrate the ability of anti-ILT4 to block the binding of ILT4 to its ligands: HLA-A and HLA-G, we blocked the interaction between R-phycoerythrin (PE)-HLA-G tetramer and ILT4-CHO cells ( Figure 8 ), or blocking the interaction between 5ug / ml PE-HLA-A tetramer and ILT4-CHO cells ( Fig. 9 Humanized antibodies Hz45.01-LALA, Hz156.03-LALA and 1E1 and a human IgG1-LALA control were tested in triplicate using serial titrations (0–15 ug / mL) in a functional blocking assay of 100 μg / mL. The data are summarized in Tables 6 and 7:
[0240] Table 6: IC values of anti-ILT4 blocking the binding of HLA-G to ILT4 50 value
[0241]
[0242] Table 7: IC values of anti-ILT4 blocking the binding of HLA-G to ILT4 50 value
[0243]
[0244] Anti-ILT4 antibodies have similar IC 50 The range effectively blocks HLA-G and HLA-A.
[0245] Example 7: Macrophage polarization study
[0246] The ability of the anti-ILT4 construct (final format, humanized antibody with LALA mutation on the Fc receptor) to polarize M2 macrophages to M1 macrophages to produce the proinflammatory cytokines TNF-a and IL-6 on macrophages differentiated in vitro was evaluated.
[0247] Human Monocyte Isolation and Macrophage Differentiation:
[0248] PBMCs were isolated from 4 healthy human donors using Ficoll-Paque gradient centrifugation. Untouched human monocytes were then purified from PBMCs using the Dynabeads Untouched Human Monocyte Kit according to the manufacturer's instructions (ThermoFisher Scientific). Monocytes were cultured in RPMI containing 10% FBS and 50 ng / mL M-CSF for 7 days to generate macrophages.
[0249] Processing of macrophages and determination of cytokine production
[0250] Macrophages were harvested and plated at 1x105 cells / well in 96-well plates. Macrophages were incubated with humanized LALA anti-ILT4 antibody or human IgG1-LALA control in serial titrations starting at 4ug / ml diluted 1:4 in the presence of 10ng / mL LPS for 24 hours. All samples were tested in triplicate. Conditioned media were then collected to analyze IL-6 and TNFa production using ELISA assay kits as per the manufacturer's instructions (R&D Systems). Fig.10 and 11 PrismGraphPad software was used to analyze ELISA data using a nonlinear regression formula and determine EC 50 The values are shown in Table 8 and Table 9.
[0251] Table 8: ECs producing TNFa 50 Value and R-squared value
[0252]
[0253] <![CDATA[R 2 ]]> Hz45.01 Hz77.01 Hz156.03 Donor 4 0.9479 0.9639 0.9736 Donor 5 0.9375 0.9687 0.9837
[0254] Table 9: IL-6 production by ECs 50 Value and R-squared value
[0255] <![CDATA[EC 50 (ng / mL)]]> Hz45.01 Hz156.03 1E1 Donor 4 6.03 8.20 3.74 Donor 5 15.92 21.3 13.92
[0256]
[0257]
[0258] The cell surface markers (ILT4, CD163, CD206) on macrophages before and after treatment were analyzed by flow cytometry. Fig.12 shown.
[0259] Macrophages from two different donors treated with anti-ILT4 antibodies produced TNF-a and IL-6 proinflammatory cytokines with EC50 values in the ng / ml range. ILT4 was expressed by macrophages before and after antibody treatment. Although the anti-ILT4 antibody had minimal effect on reducing CD206 expression, CD163 surface expression was reduced on macrophages from both donors. CD163 is considered an M2 marker. Taken together, these data suggest that anti-ILT4 treatment reprograms M2 to M1 macrophages by reducing CD163 expression and induces the production of TNF-a and IL-6 proinflammatory cytokines.
[0260] Example 8: Macrophage mixed leukocyte reaction (MLR) assay
[0261] Evaluation of the drug as a single treatment or in combination with anti-PD1 antibodies (eg Fig.13 Effect of humanized LALA anti-ILT4 antibody treatment on macrophages to enhance CD4 T cell activation (shown).
[0262] Human Monocyte Isolation and Macrophage Differentiation:
[0263] PBMCs were isolated from healthy human donors by Ficoll-Paque gradient centrifugation. Human monocytes were then purified from PBMCs using the EasySep Human Monocyte Isolation Kit (StemCell) according to the manufacturer's instructions.
[0264] Human monocyte differentiation and culture assay
[0265] Adjust the cell density to 0.5×10e6 cells / ml in fresh differentiation medium (STEMCELL) and for each donor, plate 10 ml / dish of mononuclear cells into five 10 cm dishes + 50 ng / ml M-CSF (add 5 ul of 100 μg / ml human M-CSF to 10 ml ImmunoCult TM -SF macrophage medium). After 4 days, half of the additional differentiation medium was added (5 ml medium per dish). After another 2 days, cells were detached into each dish using 5 ml of Versene solution, centrifuged and resuspended in RPMI + 10% FBS + 1% P / S.
[0266] The cells were counted and prepared at a density of 0.5×10e6 cells / ml in RPMI+10% FBS+1% P / S medium. 100ul of cell suspension was added to the designed wells of two 96-well U-bottom plates according to the plate map. Anti-ILT4 antibody (humanized LALA) was added to the designed wells (96-well plate) at a final concentration of 1ug / ml.
[0267] CD4+ T cells were isolated from different donors and prepared at a density of 5×10e6 cells / ml, and the cell suspension was added to the designed wells. The plate was incubated at 37°C 5% CO2 for 5 days. On the 6th day, pipette up and down and transfer all the solution to a V-bottom plate. Centrifuge and collect 100ul of the supernatant from the 96-well plate for IFN-g cytokine analysis.
[0268] Using IFN-g as a readout for T cell activation, IFN-g production was observed when given as a single agent compared to isotype control. Fig.13 As shown, increased IFN-g production was observed when combined with anti-PD1 (tolipimumab).
[0269] Example 9: Competition of anti-ILT4 mAb binding to ILT4-CHO
[0270] A competitive binding assay was performed. The assay involved testing Hz54.01-LALA (SEQ ID NO: 124 (HC), 125 (LC)), Hz156.03-LALA (SEQ ID NO: 128 (HC), 129 (LC)), 1E1, J19h1, R&D Systems MAB2078R and human IgG1-LALA in a competitive binding assay with Alexa Fluor 647 (AF647)-Hz45.01-LALA or AF647-Hz156.03-LALA for binding to ILT4-CHO cells using a continuous titration solution (0-15 μg / mL). Binding activity was measured by flow cytometry.
[0271] Anti-human ILT4 mAb was incubated with ILT4-CHO cells at various concentrations (0-15 ug / ml). Cells were washed and stained with AF647-Hz45.01-LALA. Cells were analyzed by flow cytometry. Fig.14 Anti-ILT4 mAbs are shown competing with AF647-Hz45.01-LALA for binding to ILT4-CHO cells. Fig.15 Competition binding of Hz45.01-LALA versus 1E1 and HuIgG1-LALA (as controls), and Hz45.01-LALA versus J19h1 and HuIgG1-LALA (as controls) are shown.
[0272] Anti-human ILT4 mAb was incubated with ILT4-CHO cells at various concentrations (0-15 ug / ml). Cells were washed and stained with AF647-Hz156.03-LALA. Cells were analyzed by flow cytometry. Fig.16Anti-ILT4 mAbs are shown competing with AF647-Hz156.03-LALA for binding to ILT4-CHO cells. Fig.17 Competition binding of Hz45.01-LALA versus 1E1 and HuIgG1-LALA (as controls), and Hz45.01-LALA versus J19h1 and HuIgG1-LALA (as controls) are shown.
[0273] All antibodies tested showed a dose-dependent blockade of binding to ILT4-CHO cells, IC 50 The values are summarized in the following table:
[0274]
[0275] like Fig.18 As shown, the binding of AF647-anti-ILT4 mAbs to ILT4-CHO cells was measured. Various concentrations (0-10 μg / ml) of AF647-Hz45.01-LALA and AF647-Hz 156.03-LALA were incubated with ILT4-CHO cells and analyzed by flow cytometry. The tested antibodies showed dose-dependent binding to ILT4-CHO cells, with EC 50 and EC 90 The values are summarized in the following table:
[0276] Hz45.01-LALA Hz156.03-LALA <![CDATA[EC 50 (mg / mL)]]> 0.1619 0.2477 <![CDATA[EC 90 (mg / mL)]]> 1.106 1.489
[0277] Hz45.01-LALA, Hz156.03-LALA, 1E1, and J19h1 competed for the binding of AF647-Hz45.01 to ILT4-CHO cells;
[0278] Hz45.01-LALA, Hz156.03-LALA, 1E1, and J19h1 also competed for the binding of AF647-Hz156.03-LALA to ILT4-CHO cells;
[0279] R&D MAB2078R and HuIgG1-LALA did not compete for the binding of AF647-Hz45.01-LALA or AF647-Hz156.03-LALA to ILT4-CHO cells;
[0280] Hz45.01-LALA and Hz156.03-LALA completely competed for the binding of AF647-Hz45.01-LALA and AF647-Hz156.03-LALA;
[0281] Under high-dose competition with 1E1 and J19h1, the binding activity of AF647-Hz45.01-LALA and AF647-Hz156.03-LALA still maintained a certain level. The data showed that Hz45.01-LALA and Hz156.03-LALA had binding properties that were more similar to each other and slightly different from those of 1E1 and J19h1.
[0282]
[0283]
[0284]
[0285]
[0286]
[0287]
[0288]
[0289]
[0290]
[0291]
[0292]
[0293]
[0294]
[0295] Bold amino acids represent the extracellular domain.
[0296] Any of the above protocols or similar variations thereof may be described in various documents associated with the drug product. Such documents may include, but are not limited to, protocols, statistical analysis plans, investigator manuals, clinical guidelines, drug guidelines, risk assessment and reconciliation procedures, prescription information, and other documents that may be associated with the drug product. It is particularly contemplated that such documents may be physically packaged into a kit with the drug product according to the present disclosure, which may be beneficial or as required by regulatory agencies.
[0297] Although the subject matter of the present disclosure has been described and illustrated in considerable detail with reference to certain illustrative embodiments (including various combinations and subcombinations of features), those skilled in the art will readily appreciate other embodiments and variations and modifications thereof that are encompassed within the scope of the present disclosure. Furthermore, the description of such embodiments, combinations, and subcombinations is not intended to convey that the claimed subject matter requires features or combinations of features other than those explicitly recited in the claims. Accordingly, the scope of the present disclosure is intended to include all modifications and variations encompassed within the spirit and scope of the appended claims.
Claims
1. An antibody or antigen-binding fragment thereof that binds to ILT4, comprising: A heavy chain variable domain, the heavy chain variable domain comprising: CDR-H1, said CDR-H1 comprising an amino acid sequence selected from the group consisting of DYYMN (SEQ ID NO: 1), GYSVN (SEQ ID NO: 9), DSYMN (SEQ ID NO: 23), GYFMN (SEQ ID NO: 30), SYWMN (SEQ ID NO: 38), DYTIH (SEQ ID NO: 46), DNYLQ (SEQ ID NO: 52), DYGMH (SEQ ID NO: 60) and TYGMS (SEQ ID NO: 68), CDR-H2, the CDR-H2 comprising an amino acid sequence selected from the group consisting of DINPNNGGTSYNQKFKG (SEQ ID NO:2), RINPYNGDIFNNQKFKG (SEQ ID NO:10), RIYPGVYRTHYNEKFKD (SEQ ID NO:17), YINPDNGVTRYNQKFKG (SEQ ID NO:24), RINPYNGDIFYNQKFKG (SEQ ID NO:31), QIYPGHGDTNYNGKFKG (SEQ ID NO:39), WFYPGTVSIKYNEKFKD (SEQ ID NO:47), PGSGNTYYSDNFTG (SEQ ID NO:53), YISSDSSTIYYADTVKG (SEQ ID NO:61), and WINTYSGEPTYADEFKG (SEQ ID NO:69), and a CDR-H3 comprising an amino acid sequence selected from the group consisting of GGAELTGTY WYFDV (SEQ ID NO:3), GTTVGGAWFAY (SEQ ID NO: 11), SGYYGGTYEE DAMDY (SEQ ID NO: 18), EGTITTDLSWFAY (SEQ ID NO:25), GITVAAGSF DV (SEQ ID NO:32), EGSELGRLFAY (SEQ ID NO:40), HEHPHYYGDSYDAMGY (SEQ ID NO:48), STVVYFDV (SEQ ID NO:54), RAAQGYVMDY (SEQ ID NO:62), and RGYDGYYYTMDY (SEQ ID NO:70); and A light chain variable domain, the light chain variable domain comprising: a CDR-L1 comprising an amino acid sequence selected from the group consisting of RASENIYSNLA (SEQ ID NO: 4), RASESVDSYGYSFLH (SEQ ID NO: 12), RASESVDNYGNTFMH (SEQ ID NO: 33), SASSVSFMY (SEQ ID NO: 41), SNYAN (SEQ ID NO: 55) and KASQSVSDDVA (SEQ ID NO: 63), CDR-L2, said CDR-L2 comprising an amino acid sequence selected from the group consisting of: GATNLAD (SEQ ID NO:5), LASNLES (SEQ ID NO:13), AATSLAD (SEQ ID NO:19), ASTNLAD (SEQ ID NO:26), RASNLES (SEQ ID NO:34), LTSNLAS (SEQ ID NO:42), (SEQ ID NO:53), GTNNRAP (SEQ ID NO:56), ASNRYT (SEQ ID NO:64) and AATNLAD (SEQ ID NO:71), and a CDR-L3 comprising an amino acid sequence selected from the group consisting of QHFWDSPFT (SEQ ID NO:6), QQSNEDLMYT (SEQ ID NO: 14), QNFWDTPYT (SEQ ID NO:20), QHFWDTPYT (SEQ ID NO:27), QQSSDHPLT (SEQ ID NO:35), QQWSSNPPT (SEQ ID NO:43), QHFWGTPYT (SEQ ID NO:49), WYSNHWV (SEQ ID NO:57), QQDYGSPT (SEQ ID NO:65) and QHFFGAPWT (SEQ ID NO:72).
2. The antibody or antigen-binding fragment thereof according to claim 1, wherein The CDR-H1 has an amino acid sequence selected from the group consisting of: DYYMN (SEQ ID NO: 1), GYSVN (SEQ ID NO: 9), DSYMN (SEQ ID NO: 23) and GYFMN (SEQ ID NO: 30), The CDR-H2 has an amino acid sequence selected from the group consisting of: DINPNNGGTSYNQKFK G (SEQ ID NO: 2), RINPYNGDIFNNQKFKG (SEQ ID NO: 10), RIYPGVYRTH YNEKFKD (SEQ ID NO: 17), YINPDNGVTRYNQKFKG (SEQ ID NO: 24) and RINPYNGDIFYNQKFKG (SEQ ID NO: 31), and The CDR-H3 has an amino acid sequence selected from the group consisting of: GGAELTGTYWYFDV (SEQ ID NO: 3), GTTVGGAWFAY (SEQ ID NO: 11), SGYYGGTYEEDAMDY (SEQ ID NO: 18), EGTITTDLSWFAY (SEQ ID NO: 25), and GITVAAGSFDV (SEQ ID NO: 32); and The CDR-L1 has an amino acid sequence selected from the group consisting of: RASENIYSNLA (SEQ ID NO: 4), RASESVDSYGYSFLH (SEQ ID NO: 12) and RASESVDNYGNTFMH (SEQ ID NO: 33), The CDR-L2 has an amino acid sequence selected from the group consisting of GATNLAD (SEQ ID NO: 5), LASNLES (SEQ ID NO: 13), AATSLAD (SEQ ID NO: 19), ASTNLAD (SEQ ID NO: 26) and RASNLES (SEQ ID NO: 34), and The CDR-L3 has an amino acid sequence selected from the group consisting of QHFWDSPFT (SEQ ID NO: 6), QQSNEDLMYT (SEQ ID NO: 14), QNFWDTPYT (SEQ ID NO: 20), QHFWDTPYT (SEQ ID NO: 27) and QQSSDHPLT (SEQ ID NO: 35).
3. The antibody or antigen-binding fragment thereof of claim 1, comprising a heavy chain variable domain CDR comprising DYYMN (SEQ ID NO: 1), DINPNNGGTSYNQKF KG (SEQ ID NO: 2), and GGAELTGTYWYFDV (SEQ ID NO: 3); and The light chain variable domain CDRs comprise RASENIYSNLA (SEQ ID NO: 4), GATNLAD (SEQ ID NO: 5) and QHFWDSPFT (SEQ ID NO: 6).
4. The antibody or antigen-binding fragment thereof of claim 1, comprising a heavy chain variable domain CDR comprising GYSVN (SEQ ID NO: 9), RINPYNGDIFNNQKFKG (SEQ ID NO: 10), and GTTVGGAWFAY (SEQ ID NO: 11); and The light chain variable domain CDRs comprise RASESVDSYGYSFLH (SEQ ID NO: 12), LASNLES (SEQ ID NO: 13) and QQSNEDLMYT (SEQ ID NO: 14).
5. The antibody or antigen-binding fragment thereof of claim 1, comprising a heavy chain variable domain CDR comprising DYYMN (SEQ ID NO: 1), RIYPGVYRTHYNEKFK D (SEQ ID NO: 17), and SGYYGGTYEEDAMDY (SEQ ID NO: 18); and The light chain variable domain CDRs comprise RASENIYSNLA (SEQ ID NO: 4), AATSLAD (SEQ ID NO: 19) and QNFWDTPYT (SEQ ID NO: 20).
6. The antibody or antigen-binding fragment thereof of claim 1, comprising a heavy chain variable domain CDR comprising DSYMN (SEQ ID NO: 23), YINPDNGVTRYNQKF KG (SEQ ID NO: 24), and EGTITTDLSWFAY (SEQ ID NO: 25); and The light chain variable domain CDRs comprise RASENIYSNLA (SEQ ID NO: 4), ASTNLAD (SEQ ID NO: 26) and QHFWDTPYT (SEQ ID NO: 27).
7. The antibody or antigen-binding fragment thereof of claim 1, comprising a heavy chain variable domain CDR comprising GYFMN (SEQ ID NO: 30), RINPYNGDIFYNQKFKG (SEQ ID NO: 31), and GITVAAGSFDV (SEQ ID NO: 32); and The light chain variable domain CDRs comprise RASESVDNYGNTFMH (SEQ ID NO: 33), RASNLES (SEQ ID NO: 34) and QQSSDHPLT (SEQ ID NO: 35).
8. The antibody or antigen-binding fragment thereof of claim 1, wherein the light chain variable domain comprises an amino acid sequence that is at least 80% identical to the following amino acid sequence: DIQMTQSPASLSISVGETVTITCRASENIYSNLAWYQQKQGKSPQVLVYGATN LADGVPSRFSGSGSGTQYSLKIKSLQSEDFGSYYCQHFWDSPFTFGSGTKLEIK(SEQ ID NO:8)、 VIVLTQSPASLAVSLGQRAAISCRASESVDSYGYSFLHWYQQKPGQPPKLLIY LASNLESGIPARFSGSGSGTDFTLTINPVEADDVATYYCQQSNEDLMYTFGGGTKL EIK(SEQ ID NO:16)、 DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYAATS LADGVPSRFRGSGSGTQYSLKISSLQSEDFGNYYCQNFWDTPYTFGGGTKLEIK(SEQ ID NO:22)、 DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYASTN LADGAPATFSGSGSGTQYSLKINSLQSVDFGSYYCQHFWDTPYTFGGGTKLEIK(SEQ ID NO:29)、 DIVLTQSPASLAVSLGQRATISCRASESVDNYGNTFMHWYQQKPGQPPKLLIY RASNLESGIPARFSGSGSKTDFTLTINPVEADDVATYYCQQSSDHPLTFGAGTKLEL S(SEQ ID NO:37)、 QIVLTQSPALMSASPGEKVTMTCSASSSVSFMYWYQQKPRSSPKPWIYLTSNL ASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPPTFGGGTKLEIK(SEQ ID NO:45)、 DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYGAT NLADGVPSRFGGSGSGTQYSLKINSLQPEDFGSYYCQHFWGTPYTFGGGTKLEIT(SEQ ID NO:51)、 QAVVTQESALTTSPGETVTLTCRSSTGTVTTSNYANWVQEKPDHLFTGLIGGT NNRAPGVPARFSGSLIGDQAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTV L(SEQ ID NO:59)、 SIVMTQTPKFLLVSAGDRVTITCKASQSVSDDVAWYQQKPGQSPKLLIYYAS NRYTGVPDRFTGSGYGTDFTFTISTVQAEDLAVYFCQQDYGSPTFGGGTKLEIK(SEQ ID NO:67), or DIQMTQSPASSLSASVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVSAATN LADGVPSRFSGSGSGTQFSLKINSLQPEDFGSYYCQHFFGAPWTFGGGTKLEIK (SEQ ID NO: 74).
9. The antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable domain comprises an amino acid sequence that is at least 80% identical to the following amino acid sequence: EVQLQQSGPELVKPGASVKISCKASGYTFTDYYMNWVKQSHGKSLEWIGDIN PNNGGTSYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCARGGAELTGTY WYFDVWGTGTTVTVSS(SEQ ID NO:7), DVQLQQSGPELVKPGNSVKISCKAAGYSFTGYSVNWVKERHGKSLEWIGRIN PYNGDIFNNQKFKGKATLTVDKSSSTAHMELRSLTSEDSAVYYCARGTTVGGAW FAYWGQGTLVTVSA(SEQ ID NO:15), QVQLKQSGAELVRPGASVKLSCRASGYTFTDYYMNWVKQRPGQGLEWIARI YPGVYRTHYNEKFKDKATLTAEKSSSTAYMELSSLTSEDSAVYFCARSGYYGGTY EEDAMDYWGQGTSVTVSS(SEQ ID NO:21), EVQLQQSGPELVIPGASVKISCKASGYTFTDSYMNWVKQSHGKSLEWIAYINP DNGVTRYNQKFKGKATLTVHKSSSTAYMELRSLTSEDSAVYYCAREGTITTDLSW FAYWGQGTLVTVSA(SEQ ID NO:28), EVHLQQSGPELVKPGASVKISCKASGYSFIGYFMNWMKQSHGKSLEWIGRIN PYNGDIFYNQKFKGKATLTVDKSSTTAHMDLLSLTSEDFAVYYCARGITVAAGSF DVWGTGTTVTVSS(SEQ ID NO:36), QVQLQQSGAELVKPGASVKISCKASGYAFSSYWMNWVKQRPGKGLEWIGQI YPGHGDTNYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCAKEGSELGRL FAYWGQGTLVTVSA(SEQ ID NO:44), QVQLQQSGTELVKPGASVKLSCKASGYIFTDYTIHWVKQRSGQGLEWIGWFY PGTVSIKYNEKFKDKATLTADRSSSIVYMELSRLTSEDSGVYFCARHEHPHYYGDS YDAMGYWGQGTSVTVSS(SEQ ID NO:50), QVQLQQSGPELVKPGASVKISCKASGYIFTDNYLQWVKQRPGQGLEWIGWIF PGSGNTYYSDNFTGKATLTVDKSSITAYMLLSSLTSEDSAVYFCSRSTVVYFDVW GTGTTVTVSS(SEQ ID NO:58), EVQLVESGGGLVKPGGSLKLSCAASGFTFSDYGMHWVRQAPEKRLEWVAYI SSDSSTIYYADTVKGRFTISSRDNAKNTLFLEMTSLRSEDTAMYYCARRAAQGYVM DYWGQGTSVTVSS(SEQ ID NO:66), or QIQLVQSGPELKKPGETVKISCKASGYTFTTYGMSWVKQAPGKGLKWMAWI NTYSGEPTYADEFKGRFAFSLETSVSTAYLQINNLKNEDTATYFCARRGYDGYYY TMDYWGQGTSVTVSS (SEQ ID NO: 73).
10. The antibody or antigen-binding fragment thereof of claim 1, wherein the light chain variable domain comprises an amino acid sequence that is at least 80% identical to the following amino acid sequence: DIQMTQSPASLSISVGETVTITCRASENIYSNLAWYQQKQGKSPQVLVYGATN LADGVPSRFSGSGSGTQYSLKIKSLQSEDFGSYYCQHFWDSPFTFGSGTKLEIK(SEQ ID NO:8), VIVLTQSPASLAVSLGQRAAISCRASESVDSYGYSFLHWYQQKPGQPPKLLIY LASNLESGIPARFSGSGSGTDFTLTINPVEADDVATYYCQQSNEDLMYTFGGGTKL EIK(SEQ ID NO:16), DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYAATS LADGVPSRFRGSGSGTQYSLKISSLQSEDFGNYYCQNFWDTPYTFGGGTKLEIK(SEQ ID NO:22), OR DIVLTQSPASLAVSLGQRATISCRASESVDNYGNTFMHWYQQKPGQPPKLLIY RASNLESGIPARFSGSGSKTDFTLTINPVEADDVATYYCQQSSDHPLTFGAGTKLEL S (SEQ ID NO: 37).
11. The antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable domain comprises an amino acid sequence that is at least 80% identical to the following amino acid sequence: EVQLQQSGPELVKPGASVKISCKASGYTFTDYYMNWVKQSHGKSLEWIGDIN PNNGGTSYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCARGGAELTGTY WYFDVWGTGTTVTVSS(SEQ ID NO:7), DVQLQQSGPELVKPGNSVKISCKAAGYSFTGYSVNWVKERHGKSLEWIGRIN PYNGDIFNNQKFKGKATLTVDKSSSTAHMELRSLTSEDSAVYYCARGTTVGGAW FAYWGQGTLVTVSA(SEQ ID NO:15), QVQLKQSGAELVRPGASVKLSCRASGYTFTDYYMNWVKQRPGQGLEWIARI YPGVYRTHYNEKFKDKATLTAEKSSSTAYMELSSLTSEDSAVYFCARSGYYGGTY EEDAMDYWGQGTSVTVSS(SEQ ID NO:21), EVQLQQSGPELVIPGASVKISCKASGYTFTDSYMNWVKQSHGKSLEWIAYINP DNGVTRYNQKFKGKATLTVHKSSSTAYMELRSLTSEDSAVYYCAREGTITTDLSW FAYWGQGTLVTVSA(SEQ ID NO:28), or EVHLQQSGPELVKPGASVKISCKASGYSFIGYFMNWMKQSHGKSLEWIGRIN PYNGDIFYNQKFKGKATLTVDKSSTTAHMDLLSLTSEDFAVYYCARGITVAAGSF DVWGTGTTVTVSS (SEQ ID NO: 36).
12. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 11, wherein the antibody or antigen-binding fragment thereof antagonizes the interaction between ILT4 and HLA-G or HLA-A.
13. The antibody or antigen-binding fragment thereof of any one of claims 1 to 11, wherein the antibody or antigen-binding fragment thereof selectively binds to ILT4 relative to other leukocyte immunoglobulin-like receptor family members.
14. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 13, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain constant region selected from the group consisting of IgG1, IgG2 or IgG4.
15. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 11, wherein the antibody or antigen-binding fragment thereof comprises a light chain constant region selected from the group consisting of κ and λ.
16. The antibody or antigen-binding fragment thereof of claims 1-11, comprising a variant Fc region of IgG1, IgG2 or IgG4, The variant Fc region of IgG1 comprises: a) amino acid substitution at position Leu234 with alanine; b) amino acid substitution at position Leu235 with alanine; c) amino acid substitution at position Pro329 with glycine or arginine; d) amino acid substitution at position Asn297 with alanine; e) amino acid substitution at position Asn297 with glutamine; f) amino acid substitution at position Asn297 with glycine; g) Any combination of (a) to (f); The variant Fc region of IgG2 comprises: h) amino acid substitution at position Ser228 with proline; i) an amino acid substitution at position Pro329 with glycine or arginine; or j) both (h) and (i); and The variant Fc region of IgG4 comprises: k) amino acid substitution at position Ser228 with proline; 1) amino acid substitution at position Leu235 with alanine or glutamic acid; m) an amino acid substitution at position Pro329 with glycine or arginine; or n) any combination of (k) to (m), The residues are numbered according to the EU index of Kabat.
17. The antibody or antigen-binding fragment thereof of any one of claims 1-11, wherein the antibody or antigen-binding fragment thereof specifically binds to human ILT4 with an affinity at least 100 times higher than the affinity with which the antibody or antigen-binding fragment thereof binds to each of human ILT3 and human ILT2.
18. The antibody or antigen-binding fragment thereof of any one of claims 1 to 11, wherein the antibody or antigen-binding fragment thereof has an equilibrium dissociation constant (K D ) binds to ILT4: less than or equal to 1 nM, less than or equal to 0.9 nM, less than or equal to 0.8 nM, less than or equal to 0.7 nM, less than or equal to 0.6 nM, less than or equal to 0.5 nM, less than or equal to 0.4 nM, less than or equal to 0.3 nM, less than or equal to 0.2 nM, less than or equal to 0.1 nM, less than or equal to 0.09 nM, or less than or equal to 0.08 nM.
19. The antibody or antigen-binding fragment thereof of any one of claims 1-11, wherein the antibody or antigen-binding fragment thereof has an equilibrium dissociation constant (K) of about 0.5 to about 10 pM, about 1 to about 9 pM, about 2 to about 8 pM, about 3 to about 7 pM, or about 4 to about 6 pM. D ) binds to ILT4.
20. The antibody or antigen-binding fragment thereof of any one of claims 1-11, wherein the antibody or antigen-binding fragment thereof has an IC of about 0.1 to about 0.25 μg / mL for blocking HLA-G binding to ILT4. 50 value.
21. The antibody or antigen-binding fragment thereof of any one of claims 1-11, wherein the antibody or antigen-binding fragment thereof has an IC of about 0.1 to about 0.2 μg / mL for blocking HLA-A binding to ILT4. 50 value.
22. The antibody or antigen-binding fragment thereof of any one of claims 1-11, wherein the antibody or antigen-binding fragment thereof has an EC of about 7 ng / mL to about 25 ng / mL or about 12 ng / mL to about 20 ng / mL for TNF-α production. 50 value.
23. The antibody or antigen-binding fragment thereof of any one of claims 1-11, wherein the antibody or antigen-binding fragment thereof has an EC of IL-6 production of about 5 ng / mL to about 25 ng / mL, about 6 ng / mL to about 22 ng / mL, or about 8 ng / mL to about 21 ng / mL. 50 value.
24. An immunoconjugate comprising the antibody or antigen-binding fragment thereof of any one of claims 1-23 coupled to a chemotherapeutic agent, a cytotoxin, a detectable moiety, a diagnostic agent, or a combination thereof.
25. A method of treating a subject having an autoimmune, neoplastic or inflammatory disorder comprising administering to the subject the antibody or antigen-binding fragment thereof of any one of claims 1-23 or the immunoconjugate of claim 24.
26. The method of claim 25, wherein the autoimmune disease is Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, ankylosing spondylitis, psoriatic arthritis, enteropathic arthritis, reactive arthritis, undifferentiated spondyloarthropathy, juvenile spondyloarthropathy, Behcet's disease, tendinitis, ulcerative colitis, Crohn's disease, irritable bowel syndrome, inflammatory bowel disease, fibromyalgia, chronic fatigue syndrome, pain disorders associated with systemic inflammatory diseases, systemic lupus erythematosus, Sjögren's syndrome, rheumatoid arthritis, juvenile rheumatoid arthritis, juvenile-onset diabetes (also known as diabetes mellitus). called type I diabetes), Wegener's granulomatosis, polymyositis, dermatomyositis, inclusion body myositis, multiple endocrine failure, Schmidt's syndrome, autoimmune uveitis, Addison's disease, Graves' disease, Hashimoto's thyroiditis, autoimmune thyroid disease, pernicious anemia, gastric atrophy, chronic hepatitis, lupus hepatitis, atherosclerosis, multiple sclerosis, amyotrophic lateral sclerosis, hypoparathyroidism, Dressler syndrome, myasthenia gravis, Lambert-Eaton syndrome, autoimmune thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic anemia, pemphigus vulgaris, Pemphigus, dermatitis herpetiformis, alopecia, scleroderma, progressive systemic sclerosis, CREST syndrome (calcification, Raynaud's phenomenon, esophageal dysmotility, scleroderma, and telangiectasia), adult-onset diabetes mellitus (also known as type 2 diabetes mellitus), mixed connective tissue disease, polyarteritis nodosa, systemic necrotizing vasculitis, glomerulonephritis, atopic dermatitis, atopic rhinitis, Goodpasture's syndrome, Chagas disease, sarcoidosis, rheumatic fever, asthma, antiphospholipid syndrome, erythema multiforme, Cushing's syndrome, autoimmune chronic active hepatitis, allergic disorders, allergic encephalomyelitis, blood transfusion reaction, leprosy, malaria, leishmaniasis, trypanosomiasis, Takayasu's arteritis, polymyalgia rheumatica, temporal arteritis, schistosomiasis, giant cell arteritis, eczema, lymphomatoid granuloma, Kawasaki disease, endophthalmitis, psoriasis, erythroblastosis fetalis, eosinophilic fasciitis, Schulman syndrome, Felty syndrome, Fuchs' cyclitis, IgA nephropathy, Kennock-Scholin purpura, graft-versus-host disease, transplant rejection, tularemia, periodic fever syndromes, septic arthritis, familial Mediterranean fever, TNF receptor-associated periodic syndrome (TRAPS), Markell-Wells syndrome, or hyper-IgD syndrome.
27. A method of delivering the antibody or antigen-binding fragment thereof of any one of claims 1-23 or the immunoconjugate of claim 24 to a subject, comprising administering the antibody or antigen-binding fragment thereof to the subject via a route of administration selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intraarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracavitary, intracerebellar, intraventricular, intracolonic, intracervical, intragastric, intrahepatic, intramyocardial, intraosseous, intrapelvic, intrapericardial, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrathecal, intra-Eumaya capsule, intravitreal, intraocular, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.
28. An expression system comprising at least one expression vector, The expression system comprises one or more nucleic acid sequences encoding a protein comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 11.
29. A host cell comprising the expression system of claim 28.
30. The host cell of claim 29, wherein the host cell is a mammalian cell.
31. The host cell of claim 29, wherein the host cell is a Chinese hamster ovary cell.
32. A method for producing an antibody or an antigen-binding fragment thereof, comprising: Cultivating the host cell of any one of claims 29 to 31 under conditions such that the antibody or antigen-binding fragment thereof is expressed, and recovering the antibody or antigen-binding fragment thereof.
33. The method of claim 32, further comprising purifying the recovered antibody or antigen-binding fragment thereof.
34. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 11 and a pharmaceutically acceptable carrier.
35. The pharmaceutical composition of claim 34, further comprising an additional therapeutic agent.
36. The pharmaceutical composition of claim 35, wherein the additional therapeutic agent is an antagonist of PD-1 / PD-L1, TIGIT or CTLA4.
37. The pharmaceutical composition of claim 36, wherein the PD-L / PD-1 antagonist is selected from the group consisting of nivolumab, pembrolizumab, atezolizumab, durvalumab, lambrolizumab, avelumab and toripalizumab.
38. The pharmaceutical composition of claim 37, wherein the PD-L / PD-1 antagonist is toripalimab.
39. A method of treating a subject having cancer, comprising administering to the subject the pharmaceutical composition of any one of claims 34-38.
40. The method of claim 39, wherein the cancer is a solid cancer or a liquid cancer.
41. The method of claim 39, wherein the cancer is a carcinoma or a sarcoma.
42. The method of claim 39, wherein the cancer is squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, glioma, gastrointestinal cancer, kidney cancer (e.g., clear cell carcinoma), ovarian cancer, liver cancer, colorectal cancer, endometrial cancer, kidney cancer (e.g., renal cell carcinoma (RCC)), prostate cancer (e.g., hormone-refractory prostate adenocarcinoma), thyroid cancer, neuroblastoma, pancreatic cancer, glioblastoma (glioblastoma multiforme), cervical cancer, gastric cancer, bladder cancer, hepatoma, breast cancer, colon cancer, head and neck cancer (or carcinoma), gastric cancer, germ cell tumor, childhood sarcoma, sinonasal natural killer cell, melanoma (e.g., metastatic malignant melanoma, such as cutaneous or intraocular malignant melanoma), bone cancer, skin cancer, uterine cancer, cancer of the anal region, testicular cancer, fallopian tube cancer, endometrial cancer, cervical cancer, Vaginal cancer, vulvar cancer, esophageal cancer, small intestinal cancer, endocrine system cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, solid tumors in children, ureteral cancer, renal pelvis cancer, central nervous system (CNS) neoplasms, primary CNS lymphoma, tumor angiogenesis, spinal cord tumors, brain cancer, brain stem glioma, pituitary adenoma, Ewing's sarcoma, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, mesothelioma, brain Membranomas, chondrosarcomas, pituitary adenomas, vestibular Schwann cell tumors, primitive neuroectodermal tumors, medulloblastomas, astrocytomas, anaplastic astrocytomas, oligodendrogliomas, ependymomas, choroid plexus papilloma, polycythemia vera, thrombocythemia, idiopathic myelofibrosis, soft tissue sarcomas, thyroid cancer, endometrial cancer, carcinoid cancer, leukemia, lymphoma, myeloma, Wilms' carcinoma, or combinations or metastases thereof.
43. The method of claim 39, wherein the cancer is acute leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML), undifferentiated AML (MO), myeloblastic leukemia (M1), myeloblastic leukemia (M2; with cell maturation), promyelocytic leukemia (M3 or M3 variant [M3V]), myelomonocytic leukemia (M4 or with eosinophilic leukemia (M5), erythroleukemia (M6), megakaryoblastic leukemia (M7), solitary granulocytic sarcoma, and chloroma; lymphomas, such as Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), B-cell lymphoma, T-cell lymphoma, lymphoplasmacytoid lymphoma, monocytoid B-cell lymphoma, mucosa-associated lymphoid tissue (MALT) lymphoma, anaplastic (e.g., Ki 1+) Large cell lymphoma, adult T-cell lymphoma / leukemia, mantle cell lymphoma, angioimmunoblastic T-cell lymphoma, angiocentric lymphoma, intestinal T-cell lymphoma, primary mediastinal B-cell lymphoma, precursor T-lymphoblastic lymphoma, T-lymphoblastic; and lymphoma / leukemia (T-Lbly / T-ALL), peripheral T-cell lymphoma, lymphoblastic lymphoma, post-transplant lymphoproliferative disorder, true histiocytic lymphoma, primary central nervous system lymphoma, Primary effusion lymphoma, B-cell lymphoma, lymphoblastic lymphoma (LBL), hematopoietic neoplasms of the lymphoid lineage, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, Burkitt lymphoma, follicular lymphoma, diffuse histiocytic lymphoma (DHL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, cutaneous T-cell lymphoma (CTLC) (also called mycosis fungoides or Sezary syndrome), and leukemia with Waldenstrom's macroglobulinemia lymphoplasmacytoid lymphoma (LPL); myelomas, such as IgG myeloma, light chain myeloma, non-secretory myeloma, smoldering myeloma (also called indolent myeloma), solitary plasmacytoma and multiple myeloma, chronic lymphocytic leukemia (CLL), hairy cell lymphoma; hematopoietic tumors of myeloid lineage, tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; seminoma, teratoma, central and peripheral nerve tumors, including astrocytoma, Schwann cell tumor; mesenchymal origin Tumors of the thyroid gland, including fibrosarcoma, rhabdomyosarcoma, and osteosarcoma; and other tumors, including melanoma, xeroderma pigmentosum, keratoacanthoma, seminoma, thyroid follicular carcinoma and teratocarcinoma, hematopoietic tumors of the lymphoid lineage, such as T-cell and B-cell tumors, including but not limited to T-cell disorders such as T-prolymphocytic leukemia (T-PLL), including small cell and cerebral cell types; large granular lymphocytic leukemia (LGL) of the T-cell type; a / dT-NHL hepatosplenic lymphoma;Peripheral / post-thymic T-cell lymphoma (pleomorphic and immunoblastic subtypes); angiocentric (nasal) T-cell lymphoma; head and neck cancer, kidney cancer, colorectal cancer, thyroid cancer; acute myeloid lymphoma, or a combination or metastasis thereof.
44. The method of claim 39, wherein the cancer is lung cancer, liver cancer, ovarian cancer, pancreatic cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, glioblastoma, kidney cancer, stomach cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, or head / neck cancer.
45. The method of claim 39, wherein the cancer is NSCLC.
46. A method for inducing apoptosis in cancer cells or cancer stem cells, comprising contacting the cancer cells or cancer stem cells with the antibody or antigen-binding fragment thereof according to any one of claims 1-11.
47. An antibody or antigen-binding fragment thereof that binds to ILT4, comprising a light chain variable domain comprising an amino acid sequence that is at least 90% identical to: DIQMTQSPASLSISVGETVTITCRASENIYSNLAWYQQKQGKSPQVLVYGATN LADGVPSRFSGSGSGTQYSLKIKSLQSEDFGSYYCQHFWDSPFTFGSGTKLEIK(SE Q ID NO:8), VIVLTQSPASLAVSLGQRAAISCRASESVDSYGYSFLHWYQQKPGQPPKLLIY LASNLESGIPARFSGSGSGTDFTLTINPVEADDVATYYCQQSNEDLMYTFGGGTKL EIK(SEQ ID NO:16), DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYAATS LADGVPSRFRGSGSGTQYSLKISSLQSEDFGNYYCQNFWDTPYTFGGGTKLEIK(SEQ ID NO:22), DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYASTN LADGAPATFSGSGSGTQYSLKINSLQSVDFGSYYCQHFWDTPYTFGGGTKLEIK(SEQ ID NO:29), DIVLTQSPASLAVSLGQRATISCRASESVDNYGNTFMHWYQQKPGQPPKLLIY RASNLESGIPARFSGSGSKTDFTLTINPVEADDVATYYCQQSSDHPLTFGAGTKLEL S(SEQ ID NO:37), QIVLTQSPALMSASPGEKVTMTCSASSSVSFMYWYQQKPRSSPKPWIYLTSNL ASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPPTFGGGTKLEIK(SEQ ID NO:45), DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYGAT NLADGVPSRFGGSGSGTQYSLKINSLQPEDFGSYYCQHFWGTPYTFGGGTKLEIT(SEQ ID NO:51), QAVVTQESALTTSPGETVTLTCRSSTGTVTTSNYANWVQEKPDHLFTGLIGGT NNRAPGVPARFSGSLIGDQAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLTV L(SEQ ID NO:59), SIVMTQTPKFLLVSAGDRVTITCKASQSVSDDVAWYQQKPGQSPKLLIYYAS NRYTGVPDRFTGSGYGTDFTFTISTVQAEDLAVYFCQQDYGSPTFGGGTKLEIK(SEQ ID NO:67), or DIQMTQSPASLSASVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVSAATN LADGVPSRFSGSGSGTQFSLKINSLQPEDFGSYYCQHFFGAPWTFGGGTKLEIK (SEQ ID NO:74); and a heavy chain variable domain comprising an amino acid sequence that is at least 90% identical to the following: EVQLQQSGPELVKPGASVKISCKASGYTFTDYYMNWVKQSHGKSLEWIGDIN PNNGGTSYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCARGGAELTGT YWYFDVWGTGTTVTVSS (SEQ ID NO:7), DVQLQQSGPELVKPGNSVKISCKAAGYSFTGYSVNWVKERHGKSLEWIGRIN PYNGDIFNNQKFKGKATLTVDKSSSTAHMELRSLTSEDSAVYYCARGTTVGGAW FAYWGQGTLVTVSA (SEQ ID NO:15), QVQLKQSGAELVRPGASVKLSCRASGYTFTDYYMNWVKQRPGQGLEWIARI YPGVYRTHYNEKFKDKATLTAEKSSSTAYMELSSLTSEDSAVYFCARSGYYGGTY EEDAMDYWGQGTSVTVSS (SEQ ID NO:21), EVQLQQSGPELVIPGASVKISCKASGYTFTDSYMNWVKQSHGKSLEWIAYINP DNGVTRYNQKFKGKATLTVHKSSSTAYMELRSLTSEDSAVYYCAREGTITTDLSW FAYWGQGTLVTVSA (SEQ ID NO:28), EVHLQQSGPELVKPGASVKISCKASGYSFIGYFMNWMKQSHGKSLEWIGRIN PYNGDIFYNQKFKGKATLTVDKSSTTAHMDLLSLTSEDFAVYYCARGITVAAGSF DVWGTGTTVTVSS (SEQ ID NO:36), QVQLQQSGAELVKPGASVKISCKASGYAFSSYWMNWVKQRPGKGLEWIGQI YPGHGDTNYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCAKEGSELGRL FAYWGQGTLVTVSA (SEQ ID NO:44), QVQLQQSGTELVKPGASVKLSCKASGYIFTDYTIHWVKQRSGQGLEWIGWFY PGTVSIKYNEKFKDKATLTADRSSSIVYMELSRLTSEDSGVYFCARHEHPHYYGDS YDAMGYWGQGTSVTVSS(SEQ ID NO:50), QVQLQQSGPELVKPGASVKISCKASGYIFTDNYLQWVKQRPGQGLEWIGWIF PGSGNTYYSDNFTGKATLTVDKSSITAYMLLSSLTSEDSAVYFCSRSTVVYFDVW GTGTTVTVSS(SEQ ID NO:58), EVQLVESGGGLVKPGGSLKLSCAASGFTFSDYGMHWVRQAPEKRLEWVAYI SSDSSTIYYADTVKGRFTISSRDNAKNTLFLEMTSLRSEDTAMYYCARRAAQGYVM DYWGQGTSVTVSS(SEQ ID NO:66), or QIQLVQSGPELKKPGETVKISCKASGYTFTTYGMSWVKQAPGKGLKWMAWI NTYSGEPTYADEFKGRFAFSLETSVSTAYLQINNLKNEDTATYFCARRGYDGYYY TMDYWGQGTSVTVSS (SEQ ID NO: 73).
48. The antibody or antigen-binding fragment thereof of claim 47, comprising a light chain variable domain comprising an amino acid sequence that is at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 8, 16, 22, 29, 37, 45, 51, 59, 67 or 74; and a heavy chain variable domain comprising an amino acid sequence that is at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 7, 15, 21, 28, 36, 44, 50, 58, 66 or 73.
49. The antibody or antigen-binding fragment thereof of claim 47, comprising a light chain variable domain comprising an amino acid sequence that is at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 8, 16, 22, 29 or 37; and a heavy chain variable domain comprising an amino acid sequence that is at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 7, 15, 21, 28 or 36.
50. The antibody or antigen-binding fragment thereof of claim 47, comprising a light chain variable domain comprising the amino acid sequence shown in SEQ ID NO: 8, 16, 22, 29 or 37; and a heavy chain variable domain comprising the amino acid sequence shown in SEQ ID NO: 7, 15, 21, 28 or 36.
51. The antibody or antigen-binding fragment thereof of claim 47, comprising: a CDR-H1 comprising an amino acid sequence of X1X2X3X4N, wherein X1 is D or G, X2 is Y or S, X3 is Y, S or F, and X4 is M or V, Contains X1IX2PX3X4X5X6X7X8X9NX 10 KFK 11 CDR-H2 of the amino acid sequence of (SEQ ID No: 76), wherein X1 is R, D or Y; X2 is N or Y; X3 is G, N, D or Y; X4 is V or N; X5 is G or Y; X6 is R, G, V or D; X7 is I or T; X8 is H, S, R, or F; X9 is Y or N; ...1 is N or Y; X1 is N or Y; X1 is N or Y; X1 is N or Y; X1 is N or Y; X1 is N or Y; X1 is N or Y; X1 is N or Y; X1 is N or Y; X1 is N or Y; X1 is N or Y; X1 is N or Y; X1 is N or Y; X1 is N or Y; X1 is N or Y; X1 is N or Y; X1 is N or Y 10 is E or Q; X 11 is D or G, and contains X1X2X3X4X5X6X7X8X9X 10 X 11 X 12 X 13 X 14 X 15 CDR-H3 of the amino acid sequence of, wherein X1 is G, S or E; X2 is G, T or I; X3 is A, T or Y; X4 is E, V, Y or I; X5 is L, G, T or A; X6 is T, G or A; X7 is G, A, T or D; X8 is T, W, Y, L or S; X9 is Y, F, E or S; X 10 W, A, E or D; X 11 is Y, D, F or V; X 12 F, A or not present; X 13 D, M, Y, or not present; X 14 is V, D or absent; and X 15 is Y or absent; and A light chain variable domain, the light chain variable domain comprising: Contains RASEX1X2X3X4X5X6X7X8X9X 10 CDR-L1 of the amino acid sequence of (SEQ ID NO: 78), wherein X1 is N or S; X2 is I or V; X3 is Y or D; X4 is S or N; X5 is N or Y; X6 is L or G; X7 is A, Y or N; X8 is S, T or absent; X9 is F or absent; X1 is N or Y; X2 is N or Y; X3 is N or Y; X4 is S or N; X5 is N or Y; X6 is L or G; X7 is A, Y or N; X8 is S, T or absent; X9 is F or absent; X1 is N or Y; X1 is N or S; X1 is N or S; X2 is I or V; X3 is Y or absent; X4 is S or N; X5 is N or Y; X6 is L or G; X7 is A, Y or N; X8 is S, T or absent; X9 is F or absent; X1 is N or S; X1 is N or S; X1 is N or 10 is L, M or does not exist, A CDR-L2 comprising an amino acid sequence of X1X2X3X4LX5X6, wherein X1 is L, R, G or A; X2 is A or S; X3 is S or T; X4 is N or S; X5 is E or A; and X6 is S or D, and A CDR-L3 comprising an amino acid sequence of X1QX2X3X4DX5X6X7T, wherein X1 is absent or is Q; X2 is S, H, N or Q; X3 is N, F or S; X4 is E, W or S; X5 is L, S, T or H; X6 is M or P; and X7 is Y, F or L.
52. The antibody or antigen-binding fragment thereof of any one of claims 47-51, wherein the antibody or antigen-binding fragment thereof antagonizes the interaction between ILT4 and HLA-G or HLA-A.
53. The antibody or antigen-binding fragment thereof of any one of claims 47-51, wherein the antibody or antigen-binding fragment thereof selectively binds to ILT4 relative to other leukocyte immunoglobulin-like receptor family members.
54. The antibody or antigen-binding fragment thereof of claims 47-51, wherein the antibody comprises a heavy chain constant region selected from the group consisting of IgG1, IgG2, or IgG4.
55. The antibody or antigen-binding fragment thereof of any one of claims 47-51, wherein the antibody comprises a light chain constant region selected from the group consisting of kappa and lambda.
56. The antibody or antigen-binding fragment thereof of claims 47-51, comprising a variant Fc region of IgG1, IgG2 or IgG4, The variant Fc region of IgG1 comprises: a) amino acid substitution at position Leu234 with alanine; b) amino acid substitution at position Leu235 with alanine; c) amino acid substitution at position Pro329 with glycine or arginine; d) amino acid substitution at position Asn297 with alanine; e) amino acid substitution at position Asn297 with glutamine; f) amino acid substitution at position Asn297 with glycine; or g) Any combination of (a) to (f); The variant Fc region of IgG2 comprises: h) amino acid substitution at position Ser228 with proline; i) an amino acid substitution at position Pro329 with glycine or arginine; or j) both (h) and (i); and The variant Fc region of IgG4 comprises: k) amino acid substitution at position Ser228 with proline; 1) amino acid substitution at position Leu235 with alanine or glutamic acid; m) an amino acid substitution at position Pro329 with glycine or arginine; or n) any combination of (k) to (m), The residues are numbered according to the EU index of Kabat.
57. The antibody or antigen-binding fragment thereof of any one of claims 47-51, wherein the antibody or antigen-binding fragment thereof specifically binds to human ILT4 with an affinity at least 100 times higher than the affinity with which the antibody or antigen-binding fragment thereof binds to each of human ILT3 and human ILT2.
58. The antibody or antigen-binding fragment thereof of any one of claims 47-51, wherein the antibody or antigen-binding fragment thereof has an equilibrium dissociation constant (K D ) binds to ILT4: less than or equal to 1 nM, less than or equal to 0.9 nM, less than or equal to 0.8 nM, less than or equal to 0.7 nM, less than or equal to 0.6 nM, less than or equal to 0.5 nM, less than or equal to 0.4 nM, less than or equal to 0.3 nM, less than or equal to 0.2 nM, less than or equal to 0.1 nM, less than or equal to 0.09 nM, or less than or equal to 0.08 nM.
59. An immunoconjugate comprising the antibody or antigen-binding fragment thereof of any one of claims 47-58 coupled to a chemotherapeutic agent, a cytotoxin, a detectable moiety, a diagnostic agent, or a combination thereof.
60. A method of treating a subject having an autoimmune, neoplastic or inflammatory disorder comprising administering to the subject the antibody or antigen-binding fragment thereof of any one of claims 47-58 or the immunoconjugate of claim 59.
61. The method of claim 60, wherein the autoimmune disease is Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, ankylosing spondylitis, psoriatic arthritis, enteropathic arthritis, reactive arthritis, undifferentiated spondyloarthropathy, juvenile spondyloarthropathy, Behcet's disease, tendinitis, ulcerative colitis, Crohn's disease, irritable bowel syndrome, inflammatory bowel disease, fibromyalgia, chronic fatigue syndrome, pain disorders associated with systemic inflammatory diseases, systemic lupus erythematosus, Sjögren's syndrome, rheumatoid arthritis, juvenile rheumatoid arthritis, juvenile-onset diabetes (also known as diabetes mellitus). called type I diabetes), Wegener's granulomatosis, polymyositis, dermatomyositis, inclusion body myositis, multiple endocrine failure, Schmidt's syndrome, autoimmune uveitis, Addison's disease, Graves' disease, Hashimoto's thyroiditis, autoimmune thyroid disease, pernicious anemia, gastric atrophy, chronic hepatitis, lupus hepatitis, atherosclerosis, multiple sclerosis, amyotrophic lateral sclerosis, hypoparathyroidism, Dressler syndrome, myasthenia gravis, Lambert-Eaton syndrome, autoimmune thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic anemia, pemphigus vulgaris, Pemphigus, dermatitis herpetiformis, alopecia, scleroderma, progressive systemic sclerosis, CREST syndrome (calcification, Raynaud's phenomenon, esophageal dysmotility, scleroderma, and telangiectasia), adult-onset diabetes mellitus (also known as type 2 diabetes mellitus), mixed connective tissue disease, polyarteritis nodosa, systemic necrotizing vasculitis, glomerulonephritis, atopic dermatitis, atopic rhinitis, Goodpasture's syndrome, Chagas disease, sarcoidosis, rheumatic fever, asthma, antiphospholipid syndrome, erythema multiforme, Cushing's syndrome, autoimmune chronic active hepatitis, allergic disorders, allergic encephalomyelitis, blood transfusion reaction, leprosy, malaria, leishmaniasis, trypanosomiasis, Takayasu's arteritis, polymyalgia rheumatica, temporal arteritis, schistosomiasis, giant cell arteritis, eczema, lymphomatoid granuloma, Kawasaki disease, endophthalmitis, psoriasis, erythroblastosis fetalis, eosinophilic fasciitis, Schulman syndrome, Felty syndrome, Fuchs' cyclitis, IgA nephropathy, Kennock-Scholin purpura, graft-versus-host disease, transplant rejection, tularemia, periodic fever syndromes, septic arthritis, familial Mediterranean fever, TNF receptor-associated periodic syndrome (TRAPS), Markell-Wells syndrome, or hyper-IgD syndrome.
62. A method of delivering the antibody or antigen-binding fragment thereof of any one of claims 47-58 or the immunoconjugate of claim 59 to a subject, comprising administering the antibody or antigen-binding fragment thereof to the subject via a route of administration selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intraarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracavitary, intracerebellar, intraventricular, intracolonic, intracervical, intragastric, intrahepatic, intramyocardial, intraosseous, intrapelvic, intrapericardial, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrathecal, intra-Eumaya capsule, intravitreal, intraocular, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.
63. An expression system comprising at least one expression vector, The expression system comprises one or more nucleic acid sequences encoding a protein comprising the antibody or antigen-binding fragment thereof described in any one of claims 47-51.
64. A host cell comprising the expression system of claim 63.
65. The host cell of claim 64, wherein the host cell is a mammalian cell.
66. The host cell of claim 64, wherein the host cell is a Chinese hamster ovary cell.
67. A method for producing an antibody or an antigen-binding fragment thereof, comprising: Cultivating the host cell of any one of claims 64-66 under conditions such that the antibody or antigen-binding fragment thereof is expressed, and recovering the antibody or antigen-binding fragment thereof.
68. The method of claim 67, further comprising purifying the recovered antibody or antigen-binding fragment thereof.
69. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 47-51 and a pharmaceutically acceptable carrier.
70. The pharmaceutical composition of claim 69, further comprising an additional therapeutic agent.
71. The pharmaceutical composition of claim 70, wherein the additional therapeutic agent is an antagonist of PD-1 / PD-L1, TIGIT, or CTLA4.
72. The pharmaceutical composition of claim 71, wherein the PD-L / PD-1 antagonist is selected from the group consisting of nivolumab, pembrolizumab, atezolizumab, durvalumab, lambrolizumab, avelumab and toripalizumab.
73. The pharmaceutical composition of claim 73, wherein the PD-L / PD-1 antagonist is toripalimab.
74. A method of treating a subject having cancer, comprising administering to the subject the pharmaceutical composition of any one of claims 69-73.
75. The method of claim 65, wherein the cancer is a solid cancer or a liquid cancer.
76. The method of claim 65, wherein the cancer is a carcinoma or a sarcoma.
77. The method of claim 65, wherein the cancer is squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, glioma, gastrointestinal cancer, kidney cancer (e.g., clear cell carcinoma), ovarian cancer, liver cancer, colorectal cancer, endometrial cancer, kidney cancer (e.g., renal cell carcinoma (RCC)), prostate cancer (e.g., hormone-refractory prostate adenocarcinoma), thyroid cancer, neuroblastoma, pancreatic cancer, glioblastoma (glioblastoma multiforme), cervical cancer, gastric cancer, bladder cancer, hepatoma, breast cancer, colon cancer, head and neck cancer (or carcinoma), gastric cancer, germ cell tumor, childhood sarcoma, sinonasal natural killer cell, melanoma (e.g., metastatic malignant melanoma, such as cutaneous or intraocular malignant melanoma), bone cancer, skin cancer, uterine cancer, cancer of the anal region, testicular cancer, fallopian tube cancer, endometrial cancer, cervical cancer, Vaginal cancer, vulvar cancer, esophageal cancer, small intestinal cancer, endocrine system cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, solid tumors in children, ureteral cancer, renal pelvis cancer, central nervous system (CNS) neoplasms, primary CNS lymphoma, tumor angiogenesis, spinal cord tumors, brain cancer, brain stem glioma, pituitary adenoma, Ewing's sarcoma, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, mesothelioma, brain Membranomas, chondrosarcomas, pituitary adenomas, vestibular Schwann cell tumors, primitive neuroectodermal tumors, medulloblastomas, astrocytomas, anaplastic astrocytomas, oligodendrogliomas, ependymomas, choroid plexus papilloma, polycythemia vera, thrombocythemia, idiopathic myelofibrosis, soft tissue sarcomas, thyroid cancer, endometrial cancer, carcinoid cancer, leukemia, lymphoma, myeloma, Wilms' carcinoma, or combinations or metastases thereof.
78. The method of claim 65, wherein the cancer is acute leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML), undifferentiated AML (MO), myeloblastic leukemia (M1), myeloblastic leukemia (M2; with cell maturation), promyelocytic leukemia (M3 or M3 variant [M3V]), myelomonocytic leukemia (M4 or with eosinophilic leukemia (M5), erythroleukemia (M6), megakaryoblastic leukemia (M7), solitary granulocytic sarcoma, and chloroma; lymphomas, such as Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), B-cell lymphoma, T-cell lymphoma, lymphoplasmacytoid lymphoma, monocytoid B-cell lymphoma, mucosa-associated lymphoid tissue (MALT) lymphoma, anaplastic (e.g., Ki 1+) Large cell lymphoma, adult T-cell lymphoma / leukemia, mantle cell lymphoma, angioimmunoblastic T-cell lymphoma, angiocentric lymphoma, intestinal T-cell lymphoma, primary mediastinal B-cell lymphoma, precursor T-lymphoblastic lymphoma, T-lymphoblastic; and lymphoma / leukemia (T-Lbly / T-ALL), peripheral T-cell lymphoma, lymphoblastic lymphoma, post-transplant lymphoproliferative disorder, true histiocytic lymphoma, primary central nervous system lymphoma, Primary effusion lymphoma, B-cell lymphoma, lymphoblastic lymphoma (LBL), hematopoietic neoplasms of the lymphoid lineage, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, Burkitt lymphoma, follicular lymphoma, diffuse histiocytic lymphoma (DHL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, cutaneous T-cell lymphoma (CTLC) (also called mycosis fungoides or Sezary syndrome), and leukemia with Waldenstrom's macroglobulinemia lymphoplasmacytoid lymphoma (LPL); myelomas, such as IgG myeloma, light chain myeloma, non-secretory myeloma, smoldering myeloma (also called indolent myeloma), solitary plasmacytoma and multiple myeloma, chronic lymphocytic leukemia (CLL), hairy cell lymphoma; hematopoietic tumors of myeloid lineage, tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; seminoma, teratoma, central and peripheral nerve tumors, including astrocytoma, Schwann cell tumor; mesenchymal origin Tumors of the thyroid gland, including fibrosarcoma, rhabdomyosarcoma, and osteosarcoma; and other tumors, including melanoma, xeroderma pigmentosum, keratoacanthoma, seminoma, thyroid follicular carcinoma and teratocarcinoma, hematopoietic tumors of the lymphoid lineage, such as T-cell and B-cell tumors, including but not limited to T-cell disorders such as T-prolymphocytic leukemia (T-PLL), including small cell and cerebral cell types; large granular lymphocytic leukemia (LGL) of the T-cell type; a / dT-NHL hepatosplenic lymphoma;Peripheral / post-thymic T-cell lymphoma (pleomorphic and immunoblastic subtypes); angiocentric (nasal) T-cell lymphoma; head and neck cancer, kidney cancer, colorectal cancer, thyroid cancer; acute myeloid lymphoma, or a combination or metastasis thereof.
79. The method of claim 65, wherein the cancer is lung cancer, liver cancer, ovarian cancer, pancreatic cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, glioblastoma, kidney cancer, stomach cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, or head / neck cancer.
80. The method of claim 65, wherein the cancer is NSCLC.
81. A method of inducing apoptosis in cancer cells or cancer stem cells, comprising contacting the cancer cells or cancer stem cells with the antibody or antigen-binding fragment thereof of any one of claims 47-51.
82. An antibody or antigen-binding fragment thereof that binds to ILT4, comprising a heavy chain variable domain CDR comprising DYYMN (SEQ ID NO: 1), IYPGVYRT (SEQ ID NO: 113), and SGYYGGTYEEDAMDY (SEQ ID NO: 18); and The light chain variable domain CDRs comprise ENIYSN (SEQ ID NO: 114), AAT and QNFWDTPYT (SEQ ID NO: 20).
83. An antibody or antigen-binding fragment thereof that binds to ILT4, comprising a heavy chain variable domain CDR comprising DYYMN (SEQ ID NO: 1), INPNNGGT (SEQ ID NO: 116), and GGAELTGTYWYFDV (SEQ ID NO: 3); and The light chain variable domain CDRs comprise ENIYS (SEQ ID NO: 117), GAT and QHFWDSPFT (SEQ ID NO: 6).
84. An antibody or antigen-binding fragment thereof that binds to ILT4, comprising a heavy chain variable domain CDR comprising GYSVN (SEQ ID NO: 9), INPYNGDI (SEQ ID NO: 119), and GTTVGGAWFAY (SEQ ID NO: 11); and The light chain variable domain CDR comprises ESVDSYGYSF (SEQ ID NO: 120), LAS, and QQSNEDLMYT (SEQ ID NO: 14).
85. An antibody or antigen-binding fragment thereof that binds to ILT4, comprising a heavy chain variable domain CDR comprising GYFMN (SEQ ID NO: 30), INPYNGDI (SEQ ID NO: 119), and GITVAAGSFDV (SEQ ID NO: 32); and The light chain variable domain CDRs comprise ESVDNYGNTF (SEQ ID NO: 122), RAS and QQSSDHPLT (SEQ ID NO: 35).
